BioMedLib Search Engine [ goto HOMEPAGE ]

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Relationship of treatment delay with surgical defect size from keratinocyte carcinoma (basal cell carcinoma and squamous cell carcinoma of the skin).

Larger keratinocyte carcinoma (KC) lesions are associated with higher morbidity.

Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

MedlinePlus Health Information. consumer health - Skin Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Eur J Cancer. 2001 May;37(7):843-8 [11313171.001]

[Cites] Br J Dermatol. 2001 Mar;144(3):476-83 [11260002.001]

[Cites] Dermatol Surg. 2001 Nov;27(11):955-9 [11737130.001]

[Cites] Br J Dermatol. 2002 Jul;147(1):48-54 [12100184.001]

[Cites] Arch Dermatol. 2002 Aug;138(8):1043-51 [12164742.001]

[Cites] Melanoma Res. 2002 Aug;12(4):389-94 [12170189.001]

[Cites] Ann Plast Surg. 2002 Oct;49(4):439-42 [12370654.001]

[Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]

[Cites] Br J Dermatol. 2004 Jul;151(1):141-7 [15270883.001]

[Cites] Br J Psychiatry. 1967 Jan;113(494):89-93 [6029373.001]

[Cites] J Dermatol Surg Oncol. 1981 Apr;7(4):311-6 [7240532.001]

[Cites] Prog Clin Biol Res. 1984;156:169-79 [6473424.001]

[Cites] J Psychosom Res. 1985;29(2):139-53 [4009515.001]

[Cites] J Am Acad Dermatol. 1988 Mar;18(3):591-8 [3351022.001]

[Cites] J Dermatol Surg Oncol. 1989 Mar;15(3):315-28 [2646336.001]

[Cites] Eur J Surg Oncol. 1989 Apr;15(2):143-8 [2703058.001]

[Cites] Arch Dermatol. 1991 Mar;127(3):356-61 [1998366.001]

[Cites] J Am Acad Dermatol. 1991 Jan;24(1):1-13 [1999506.001]

[Cites] Postgrad Med. 1991 Mar;89(4):151-2, 155-8 [2000349.001]

[Cites] Ann R Coll Surg Engl. 1991 Jul;73(4):248-52 [1863047.001]

[Cites] J Dermatol Surg Oncol. 1991 Sep;17(9):713-8 [1890243.001]

[Cites] Cancer. 1991 Nov 1;68(9):2064-8 [1913555.001]

[Cites] Dermatol Surg. 1996 Mar;22(3):255-61 [8599737.001]

[Cites] J Am Acad Dermatol. 1997 Sep;37(3 Pt 1):422-9 [9308558.001]

[Cites] Arch Dermatol. 1999 Mar;135(3):269-74 [10086447.001]

[Cites] Arch Dermatol. 1999 Mar;135(3):339-40 [10086457.001]

[Cites] J Clin Epidemiol. 1999 Nov;52(11):1111-6 [10527006.001]

[Cites] Br J Dermatol. 1999 Nov;141(5):783-7 [10583157.001]

[Cites] Br J Dermatol. 1999 Nov;141(5):876-9 [10583170.001]

[Cites] Int J Cancer. 2000 May 20;89(3):271-9 [10861504.001]

[Cites] Int J Cancer. 2000 May 20;89(3):280-5 [10861505.001]

[Cites] Arch Dermatol. 2001 Aug;137(8):1055-8 [11493098.001]

(PMID = 15675948.001).

[ISSN] 0022-202X

[Journal-full-title] The Journal of investigative dermatology

[ISO-abbreviation] J. Invest. Dermatol.

[Language] ENG

[Grant] United States / NIMH NIH HHS / MH / K24 MH063975; United States / NCI NIH HHS / CA / R01 CA078800; United States / AHRQ HHS / HS / T32 HS000011; United States / NCI NIH HHS / CA / CA 78800

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.

[Publication-country] United States

[Other-IDs] NLM/ NIHMS12744; NLM/ PMC1613794

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] F-18 FDG PET as an imaging tool for detecting and staging metastatic basal-cell carcinoma.

[MeSH-major] Carcinoma, Basal Cell / radionuclide imaging. Fluorodeoxyglucose F18. Radiopharmaceuticals. Skin Neoplasms / radionuclide imaging. Tomography, Emission-Computed

[MeSH-minor] Diagnosis, Differential. Humans. Male. Middle Aged. Neoplasm Metastasis. Whole Body Imaging

MedlinePlus Health Information. consumer health - Skin Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17515767.001).

[ISSN] 0363-9762

[Journal-full-title] Clinical nuclear medicine

[ISO-abbreviation] Clin Nucl Med

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

For Fe/Cu nanoparticles, a Cu shell ∼ 20 monolayers thick appears similar in structure to bulk Cu and is sufficient to cause the structure in the Fe core to switch from body centred cubic (bcc; as in bulk Fe) to face centred cubic.

This is not the case for thinner Cu shells, 1-2 monolayers in thickness, in which there is a considerable contraction in nearest-neighbour interatomic distance as the shell structure changes to bcc.

In Fe/Au nanoparticles, the crystal structure in the Fe core remains bcc for all Au thicknesses although there is some stretching of the lattice.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. IRON, ELEMENTAL .

Hazardous Substances Data Bank. COPPER, ELEMENTAL .

Hazardous Substances Data Bank. GOLD, ELEMENTAL .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 21386550.001).

[ISSN] 1361-648X

[Journal-full-title] Journal of physics. Condensed matter : an Institute of Physics journal

[ISO-abbreviation] J Phys Condens Matter

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Chemical-registry-number] 7440-57-5 / Gold; 789U1901C5 / Copper; E1UOL152H7 / Iron

   

Advertisement

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The type strain is RV152(T) (BCC 25967(T)=NBRC 103864(T)=CBS 10864(T)).

The type strain is EA1(T) (BCC 29900(T)=NBRC 104877(T)=CBS 11021(T)).

The type strain is ST84(T) (BCC 8320(T)=NBRC 105671(T)=CBS 10931(T)).

SILVA. SILVA LSU Database .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19765089.001).

[ISSN] 1567-1364

[Journal-full-title] FEMS yeast research

[ISO-abbreviation] FEMS Yeast Res.

[Language] eng

[Databank-accession-numbers] GENBANK/ AB332397/ AB332399/ AB332401/ AB332402/ AB332403/ AB439256/ AB495287/ AB495288/ DQ404448

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / DNA, Fungal; 0 / DNA, Ribosomal Spacer

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Dermoscopic pattern of intermediate stage in seborrhoeic keratosis regressing to lichenoid keratosis: report of 24 cases.

OBJECTIVES: To evaluate the dermoscopic criteria of a series of cases of LK with remaining areas of seborrhoeic keratosis which were both dermoscopically and histologically diagnosed.

), at 10-fold magnification, at the Dermatology Department of Hospital de Sant Pau i Santa Tecla (Tarragona, Spain), between 1 January 2003 and 31 December 2005.

RESULTS: In total, 24 cases of lesions with dermoscopic areas of seborrhoeic keratosis and LK were collected.

In four lesions (17%), the clinical differential diagnosis without dermoscopy included malignant melanoma and in seven lesions (29%), basal cell carcinoma.

The diagnosis of LK was clinically considered without dermoscopy in only six cases (25%).

This pattern consisted of the presence of brownish-grey, bluish-grey or whitish-grey coarse granules that formed, in 11 cases (46%), globules and/or short lines.

[MeSH-major] Keratosis / diagnosis. Lichenoid Eruptions / diagnosis

[MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Basal Cell / diagnosis. Dermoscopy. Diagnosis, Differential. Disease Progression. Female. Humans. Keratosis, Seborrheic / diagnosis. Keratosis, Seborrheic / pathology. Male. Melanoma / diagnosis. Middle Aged. Prospective Studies. Skin Neoplasms / diagnosis

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17553042.001).

[ISSN] 0007-0963

[Journal-full-title] The British journal of dermatology

[ISO-abbreviation] Br. J. Dermatol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Eyelid carcinoma in patients with systemic lymphoma.

PURPOSE: To describe a series of patients with Non-Hodgkin's lymphoma (NHL) and concomitant eyelid carcinoma.

METHODS: In this non-comparative interventional case series, we retrospectively reviewed the medical records of 5 patients with NHL who developed eyelid carcinoma.

Systemic lymphoma had been diagnosed 1 to 72 months prior to development of the eyelid carcinoma.

The lesions were basal cell carcinoma in three, and squamous cell carcinoma in two cases.

Four patients underwent surgical excision of the carcinoma and one patient was awaiting surgical treatment after completing systemic chemotherapy.

Three subjects had high-grade carcinomas.

CONCLUSIONS: Systemic lymphoma may be associated with aggressive eyelid carcinomas.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] JAMA. 1975 Apr 21;232(3):267-9 [47401.001]

[Cites] J Natl Cancer Inst. 1978 Aug;61(2):337-40 [277720.001]

[Cites] J Natl Cancer Inst. 1992 Sep 16;84(18):1422-7 [1512794.001]

[Cites] BMJ. 1995 Jun 10;310(6993):1491-5 [7787593.001]

[Cites] Curr Opin Hematol. 2000 Jul;7(4):223-34 [10882178.001]

[Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):199-209 [15687363.001]

[Cites] Ophthal Plast Reconstr Surg. 2008 Nov-Dec;24(6):444-9 [19033839.001]

[Cites] Am J Ophthalmol. 1986 Apr 15;101(4):480-2 [3515953.001]

[Cites] Arch Ophthalmol. 1980 Oct;98(10):1771-2 [7000053.001]

[Cites] Eur J Haematol. 1994 Oct;53(4):218-22 [7957806.001]

[Cites] Br J Cancer. 1996 Dec;74(11):1847-50 [8956805.001]

[Cites] Acta Haematol. 1997;98(1):44-6 [9210914.001]

[Cites] Int J Cancer. 1999 Mar 1;80(5):641-5 [10048959.001]

[Cites] Dermatology. 2001;202(4):359-61 [11455161.001]

[Cites] J Am Acad Dermatol. 2002 Jul;47(1):1-17; quiz 18-20 [12077575.001]

[Cites] Curr Treat Options Oncol. 2004 Jun;5(3):215-23 [15115650.001]

[Cites] Leuk Lymphoma. 2004 Mar;45(3):507-13 [15160912.001]

[Cites] Histopathology. 2004 Aug;45(2):162-70 [15279635.001]

[Cites] Arch Dermatol. 2004 Aug;140(8):985-8 [15313816.001]

[Cites] Oncogene. 2004 Aug 23;23(38):6524-34 [15322522.001]

[Cites] Leuk Lymphoma. 2005 Jan;46(1):49-54 [15621780.001]

[Cites] Dermatol Surg. 2005 Jan;31(1):38-42; discussion 42 [15720094.001]

[Cites] Leuk Lymphoma. 2005 Jul;46(7):1051-5 [16019557.001]

[Cites] Skinmed. 2005 Sep-Oct;4(5):300-4 [16282752.001]

[Cites] Australas J Dermatol. 2006 Nov;47(4):231-6 [17034463.001]

(PMID = 22737325.001).

[ISSN] 2008-2010

[Journal-full-title] Journal of ophthalmic & vision research

[ISO-abbreviation] J Ophthalmic Vis Res

[Language] eng

[Publication-type] Journal Article

[Publication-country] Iran

[Other-IDs] NLM/ PMC3380669

[Keywords] NOTNLM ; Eyelid Cancer / Immunosuppression / Squamous Cell Carcinoma / Systemic Lymphoma

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Planar metal surfaces that are rough on the atomic scale, such as bcc W(111), fcc Ir(210) and hcp Re(1231), are morphologically unstable when covered by monolayer films of oxygen, or by certain other gases or metals, becoming "nanotextured" when heated to temperatures above approximately 700 K.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18818829.001).

[ISSN] 0306-0012

[Journal-full-title] Chemical Society reviews

[ISO-abbreviation] Chem Soc Rev

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Because of the crucial role of electrostatics in solvation free energy, the results from various commonly used charge generation models based on the semiempirical (AM1-BCC) and QM calculations [charge fitting using ChelpG and RESP] are compared.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 26609601.001).

[ISSN] 1549-9618

[Journal-full-title] Journal of chemical theory and computation

[ISO-abbreviation] J Chem Theory Comput

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Cytokeratin contents of basal cell carcinoma, epidermis overlying tumour, and associated stromal amyloidosis: an immunohistochemical study.

We investigated the expression of CKs immunohistochemically in basal cell carcinomas (BCCs), epidermis overlying tumour, and skin tumor-associated amyloidosis (STA).

Twenty cases of BCC, 11 of which had STA were included to the study.

In BCCs without STA, CK1-8, CK14 and CK17 antibodies were expressed by tumour tissue in all biopsy specimens.

In the BCCs with STA, tumour tissue was immunoreactive always with CK1-8 and CK17 antibodies, and commonly immunoreactive with anti-CK 14 antibody.

In conclusion, we could not find a significant CK expression difference between BCCs with and without STA.

Weak positivity and a few number of CKs were shown in STA when compared with those of BCC and epidermis overlying tumour tissue expressing the more variable CKs.

[MeSH-major] Amyloidosis / metabolism. Carcinoma, Basal Cell / metabolism. Epidermis / metabolism. Keratins / metabolism. Skin Neoplasms / metabolism. Stromal Cells / metabolism

Genetic Alliance. consumer health - Amyloidosis.

MedlinePlus Health Information. consumer health - Amyloidosis.

MedlinePlus Health Information. consumer health - Skin Cancer.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16076610.001).

[ISSN] 1350-6129

[Journal-full-title] Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis

[ISO-abbreviation] Amyloid

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 68238-35-7 / Keratins

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Genetic variants in pigmentation genes, pigmentary phenotypes, and risk of skin cancer in Caucasians.

Although a large number of single nucleotide polymorphisms (SNPs) have been identified in pigmentation genes, very few SNPs have been examined in relation to human pigmentary phenotypes and skin cancer risk.

We evaluated the associations between 15 SNPs in 8 candidate pigmentation genes (TYR, TYRP1, OCA2, SLC24A5, SLC45A2, POMC, ASIP and ATRN) and both pigmentary phenotypes (hair color, skin color and tanning ability) and skin cancer risk in a nested case-control study of Caucasians within the Nurses' Health Study (NHS) among 218 melanoma cases, 285 squamous cell carcinoma (SCC) cases, 300 basal cell carcinoma (BCC) cases and 870 common controls.

We found that the TYR Arg402Gln variant was significantly associated with skin color (p-value = 7.7 x 10(-4)) and tanning ability (p-value = 7.3 x 10(-4)); the SLC45A2 Phe374Leu variant was significantly associated with hair color (black to blonde) (p-value = 2.4 x 10(-7)), skin color (p-value = 1.1 x 10(-7)) and tanning ability (p-value = 2.5 x 10(-4)).

No significant associations were found between these polymorphisms and the risk of skin cancer.

The OCA2 Arg419Gln and ASIP g.8818 A>G were associated with BCC risk (OR, 1.50; 95% CI, 1.06-2.13 and OR, 0.73; 95% CI, 0.53-1.00, respectively).

The haplotype near ASIP (rs4911414[T] and rs1015362[G]) was significantly associated with fair skin color (OR, 2.28; 95% CI, 1.46-3.57) as well as the risks of melanoma (OR, 1.68; 95% CI, 1.18-2.39) and SCC (OR, 1.54; 95% CI, 1.08-2.19).

Our study provides evidence for the contribution of pigmentation genetic variants, in addition to the MC1R variants, to variation in human pigmentary phenotypes and possibly the development of skin cancer.

MedlinePlus Health Information. consumer health - Skin Cancer.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Nature. 1993 Jan 7;361(6407):72-6 [8421497.001]

[Cites] Ann Epidemiol. 1990 Oct;1(1):13-23 [1669486.001]

[Cites] J Clin Invest. 1994 May;93(5):2258-62 [8182158.001]

[Cites] Hum Mol Genet. 1994;3 Spec No:1469-75 [7849740.001]

[Cites] Annu Rev Genet. 1994;28:189-217 [7893123.001]

[Cites] Nat Genet. 1995 Jan;9(1):92-5 [7704033.001]

[Cites] Hum Mol Genet. 1995 Feb;4(2):223-30 [7757071.001]

[Cites] Nat Genet. 1995 Nov;11(3):328-30 [7581459.001]

[Cites] Genomics. 1995 Sep 1;29(1):24-34 [8530077.001]

[Cites] Int J Epidemiol. 1996 Apr;25(2):245-51 [9119548.001]

[Cites] Pigment Cell Res. 1996 Aug;9(4):191-203 [8948501.001]

[Cites] Am J Med Genet. 1997 Jul 11;71(1):57-62 [9215770.001]

[Cites] Exp Clin Immunogenet. 1998;15(1):19-32 [9619397.001]

[Cites] J Hered. 1998 Nov-Dec;89(6):546-51 [9864865.001]

[Cites] Nature. 1999 Mar 11;398(6723):152-6 [10086356.001]

[Cites] Ann Hum Genet. 1964 Sep;28:27-37 [14204850.001]

[Cites] Hum Mutat. 2005 Mar;25(3):278-84 [15714523.001]

[Cites] Genet Epidemiol. 2005 Apr;28(3):261-72 [15637718.001]

[Cites] Hum Genet. 2005 Apr;116(5):402-6 [15726415.001]

[Cites] Eur J Hum Genet. 2005 Aug;13(8):913-20 [15889046.001]

[Cites] J Dermatol Sci. 2005 Nov;40(2):133-6 [16183259.001]

[Cites] Science. 2005 Dec 16;310(5755):1782-6 [16357253.001]

[Cites] Pigment Cell Res. 2006 Feb;19(1):76-89 [16420249.001]

[Cites] Pigment Cell Res. 2006 Jun;19(3):226-31 [16704456.001]

[Cites] Int J Cancer. 2006 Oct 15;119(8):1976-84 [16721784.001]

[Cites] Nature. 2006 Sep 21;443(7109):340-4 [16988713.001]

[Cites] Nat Genet. 2007 Dec;39(12):1443-52 [17952075.001]

[Cites] Nat Genet. 2008 Mar;40(3):340-5 [18246066.001]

[Cites] Nat Genet. 2008 May;40(5):491-2 [18443580.001]

[Cites] PLoS Genet. 2008 May;4(5):e1000074 [18483556.001]

[Cites] Nat Genet. 2008 Jul;40(7):838-40 [18488026.001]

[Cites] Nat Genet. 2008 Jul;40(7):886-91 [18488027.001]

[Cites] Nat Genet. 2008 Jul;40(7):835-7 [18488028.001]

[Cites] PLoS One. 2008;3(7):e2551 [18596976.001]

[Cites] Nature. 2007 Feb 22;445(7130):843-50 [17314970.001]

[Cites] Am J Hum Genet. 2000 Jan;66(1):176-86 [10631149.001]

[Cites] Ann N Y Acad Sci. 1999 Oct 20;885:254-61 [10816658.001]

[Cites] J Hum Evol. 2000 Jul;39(1):57-106 [10896812.001]

[Cites] J Invest Dermatol. 2000 Oct;115(4):607-13 [10998131.001]

[Cites] Hum Mol Genet. 2000 Oct 12;9(17):2531-7 [11030758.001]

[Cites] Pigment Cell Res. 2000;13 Suppl 8:48-53 [11041357.001]

[Cites] Pigment Cell Res. 2000;13 Suppl 8:110-7 [11041367.001]

[Cites] Nat Genet. 2001 Jan;27(1):40-7 [11137996.001]

[Cites] Exp Cell Res. 2001 Jan 15;262(2):197-208 [11139343.001]

[Cites] Am J Hum Genet. 2001 Apr;68(4):884-94 [11254446.001]

[Cites] J Invest Dermatol. 2001 Aug;117(2):294-300 [11511307.001]

[Cites] Ann Hum Genet. 2006 Nov;70(Pt 6):802-11 [17044855.001]

[Cites] Int J Epidemiol. 2006 Dec;35(6):1514-21 [16943234.001]

[Cites] Hum Mutat. 2007 Jul;28(7):710-7 [17358008.001]

[Cites] Nat Genet. 2007 Jul;39(7):870-4 [17529973.001]

[Cites] Am J Hum Genet. 2007 Nov;81(5):1084-97 [17924348.001]

[Cites] Pigment Cell Res. 2001 Oct;14(5):337-47 [11601655.001]

[Cites] Gene. 2001 Oct 17;277(1-2):49-62 [11602344.001]

[Cites] Melanoma Res. 2002 Oct;12(5):513-9 [12394194.001]

[Cites] Mol Biol Cell. 2002 Dec;13(12):4206-20 [12475946.001]

[Cites] Ann N Y Acad Sci. 2003 Jun;994:133-40 [12851308.001]

[Cites] Cancer Detect Prev. 2003;27(4):311-5 [12893080.001]

[Cites] Annu Rev Genet. 2003;37:67-90 [14616056.001]

[Cites] Pflugers Arch. 2004 Feb;447(5):683-8 [14770312.001]

[Cites] Exp Cell Res. 2004 Aug 15;298(2):521-34 [15265699.001]

[Cites] Am J Hum Genet. 2004 Nov;75(5):739-51 [15372380.001]

[Cites] Am J Phys Anthropol. 1981 Jun;55(2):203-8 [7258341.001]

[Cites] Am J Epidemiol. 1986 May;123(5):894-900 [3962971.001]

[Cites] Hum Mol Genet. 2001 Oct 1;10(21):2397-402 [11689486.001]

[Cites] Am J Hum Genet. 2002 Mar;70(3):770-5 [11833005.001]

[Cites] Cancer Epidemiol Biomarkers Prev. 2002 Aug;11(8):782-4 [12163334.001]

(PMID = 19384953.001).

[ISSN] 1097-0215

[Journal-full-title] International journal of cancer

[ISO-abbreviation] Int. J. Cancer

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / R03 CA132175-02; United States / NCI NIH HHS / CA / R03 CA132175; United States / NCI NIH HHS / CA / R03 CA128080-02; United States / NCI NIH HHS / CA / CA128080; United States / NCI NIH HHS / CA / CA132175; United States / NCI NIH HHS / CA / CA128080-02; United States / NCI NIH HHS / CA / CA132175-02; United States / NCI NIH HHS / CA / R03 CA128080

[Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural

[Publication-country] United States

[Chemical-registry-number] 0 / ASIP protein, human; 0 / ATRN protein, human; 0 / Agouti Signaling Protein; 0 / Antiporters; 0 / Membrane Glycoproteins; 0 / Membrane Proteins; 0 / Membrane Transport Proteins; 0 / Neoplasm Proteins; 0 / OCA2 protein, human; 0 / SLC24A5 protein, human; 0 / SLC44A2 protein, human; EC 1.- / Oxidoreductases; EC 1.14.18.- / TYRP1 protein, human; EC 3.4.- / Proprotein Convertases

[Other-IDs] NLM/ NIHMS92488; NLM/ PMC2700213

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Breast cancer and bone mass in older women: is bone density prescreening for mammography useful?

This case-control study compares BMD at multiple sites in women with and without breast cancer to determine if BMD prescreening is useful in selecting women for continued screening mammograms.

METHODS: Women diagnosed with breast cancer in the preceding 4 months and age-matched controls (+/-2 years) with a normal mammogram, all aged 65 years and older, were recruited on a 1:2 basis; 237 women participated: 79 women (cases) with breast cancer and 158 controls.

RESULTS: Among women with breast cancer, 17.1% had stage 0, 41.5% stage I, 40.0% stage II, and 1.4% stage III.

Women with breast cancer had larger waist circumferences (p=0.002) and waist-hip ratios (p=0.01), and they exercised less (p=0.002) than women of the control group.

However, there were no differences between the cases and controls for age, obesity, and reproductive and menopausal history variables, or other covariates (p>0.10).

There were no differences in lumbar spine, total hip, femoral neck, midshaft radius, or total body BMD (p>0.10), although the cases had higher BMD at the ultradistal radius than the controls (means: 0.527 vs. 0.516, respectively; p=0.014).

There were no differences in breast cancer risk by tertile of BMD or osteoporosis status at the hip or spine.

CONCLUSION: There is little difference in BMD between women with and without breast cancer.

BMD is not useful as a prescreening predicator of mammography in older women and using it as such would result in cases of breast cancer being missed.

[MeSH-major] Bone Density. Breast Neoplasms / etiology. Mammography

[MeSH-minor] Aged. Aged, 80 and over. Case-Control Studies. Exercise. Female. Humans. Risk Factors. Vitamin D / administration & dosage

Genetic Alliance. consumer health - Bone Cancer.

Genetic Alliance. consumer health - Breast Cancer.

MedlinePlus Health Information. consumer health - Bone Density.

MedlinePlus Health Information. consumer health - Breast Cancer.

MedlinePlus Health Information. consumer health - Mammography.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Bone. 2003 Mar;32(3):211-6 [12667548.001]

[Cites] Cancer Causes Control. 1994 Nov;5(6):523-8 [7827239.001]

[Cites] Am J Epidemiol. 1990 Nov;132(5):877-83 [2239902.001]

[Cites] Environ Health Perspect. 1997 Apr;105 Suppl 3:583-5 [9167999.001]

[Cites] JAMA. 1999 Dec 8;282(22):2156-63 [10591338.001]

[Cites] J Clin Endocrinol Metab. 1995 Apr;80(4):1118-23 [7714079.001]

[Cites] J Natl Cancer Inst. 1998 Jun 3;90(11):814-23 [9625169.001]

[Cites] Am J Epidemiol. 2001 Jun 1;153(11):1071-8 [11390325.001]

[Cites] Endocr Rev. 1994 Jun;15(3):275-300 [8076582.001]

[Cites] J Natl Cancer Inst. 1995 Feb 1;87(3):190-7 [7707406.001]

[Cites] Ann Intern Med. 1997 Dec 1;127(11):955-65 [9412300.001]

[Cites] World Health Organ Tech Rep Ser. 1994;843:1-129 [7941614.001]

[Cites] Cancer Epidemiol Biomarkers Prev. 1996 Jul;5(7):533-9 [8827358.001]

[Cites] Science. 1988 Jul 1;241(4861):84-6 [3388021.001]

[Cites] JAMA. 1996 Nov 6;276(17):1404-8 [8892715.001]

[Cites] J Natl Cancer Inst. 2001 Jun 20;93(12):930-6 [11416114.001]

[Cites] Bone Miner. 1993 Feb;20(2):141-9 [8453330.001]

[Cites] J Clin Epidemiol. 2001 Apr;54(4):417-22 [11297892.001]

[Cites] Environ Health Perspect. 1997 Apr;105 Suppl 3:593-9 [9168001.001]

[Cites] J Chronic Dis. 1987;40(2):105-13 [3818863.001]

[Cites] J Am Acad Nurse Pract. 2001 Jun;13(6):276-84 [11930870.001]

[Cites] N Engl J Med. 1997 Feb 27;336(9):611-7 [9032046.001]

[Cites] Eur J Cancer. 1998 Jul;34(8):1163-74 [9849474.001]

[Cites] JAMA. 1999 Jun 16;281(23):2189-97 [10376571.001]

(PMID = 16699738.001).

[ISSN] 0937-941X

[Journal-full-title] Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA

[ISO-abbreviation] Osteoporos Int

[Language] eng

[Grant] United States / NCRR NIH HHS / RR / M01 RR00827

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.

[Publication-country] England

[Chemical-registry-number] 1406-16-2 / Vitamin D

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Surgical treatment of scalp malignant tumor].

OBJECTIVE: To investigate the effects of different surgical methods in treating scalp malignant tumors.

METHODS: From January 1995 to September 2004, 70 patients with scalp malignant tumor were treated with different surgical methods.

The course of disease ranged from 2 weeks to 3 years (mean 3.5 months).

There were 31 cases of basal cell carcinoma, 24 cases of squamous carcinoma, 8 cases of melanocarcinoma, 4 cases of fibrous sarcoma, 2 cases of liposarcoma, and 1 case of vasculosarcoma.

Defect was repaired withfree skin transplantation in 51 cases, scalp flap in 12 cases, cervico-shoulder flap in 2 cases, trapizius myocutaneous flap in 3 cases, and radial artery retro-island flap in 2 cases.

RESULTS: Of 70 cases, 67 skin flaps survived and incision healed by first intention; 2 flaps necrosed at distal part (< 1 cm) and healed by second intention after dressing change; 1 flap infected and was treated with symptomatic medication.

Fifty-five patients were followed up for 1 to 5 years and 5 cases had tumor recurrence.

In patients receiving skin transplantation, 1 case of squamous carcinoma and 1 case of fibrous sarcoma relapsed after 1 year and 2.5 years respectively and were given radical resection and skin flap grafting; in patients receiving skin flap grafting, 1 case of vasculosarcoma and 1 case of squamous carcinoma relapsed after 6 months and 3 months respectively, and gave up treatment; 1 case of fibrous sarcoma relapsed after 2 years and was given radical resection and skin flap grafting.

The other cases survived and had no tumor recurrence.

CONCLUSION: Scalp malignant tumors should be diagnosised and treated as early as possible.

[MeSH-major] Carcinoma, Squamous Cell / surgery. Scalp. Skin Neoplasms / surgery. Skin Transplantation / methods. Surgical Flaps

MedlinePlus Health Information. consumer health - Skin Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18361240.001).

[ISSN] 1002-1892

[Journal-full-title] Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery

[ISO-abbreviation] Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi

[Language] chi

[Publication-type] English Abstract; Journal Article

[Publication-country] China

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Cutaneous squamous cell carcinoma of the external auditory canal.

Cutaneous squamous cell carcinoma (SCC) along with basal cell carcinoma (BCC), collectively known as Nonmelanoma skin cancer (NMSC), are the most common cancers in the United States.

Squamous cell carcinoma of the skin is less common than BCC, but is known to be more aggressive with a higher mortality rate.

Squamous cell carcinoma of the external auditory canal (EAC) is rare when compared to SCC on other cutaneous sites.

This is a case of a 76-year-old man who initially presented with actinic keratosis of the EAC that died in just over a year from metastatic cutaneous SCC.

[MeSH-major] Carcinoma, Squamous Cell / pathology. Ear Canal. Neoplasm Invasiveness / pathology. Otologic Surgical Procedures / methods. Skin Neoplasms / pathology

[MeSH-minor] Aged. Fatal Outcome. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Neoplasm Staging. Risk Assessment. Surgical Flaps. Time Factors. Treatment Outcome

Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

MedlinePlus Health Information. consumer health - Skin Cancer.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19336030.001).

[ISSN] 1087-2108

[Journal-full-title] Dermatology online journal

[ISO-abbreviation] Dermatol. Online J.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Radiotherapy for perineural invasion in cutaneous head and neck carcinomas: toward a risk-adapted treatment approach.

BACKGROUND: We retrospectively reviewed outcomes in patients treated with radiotherapy (RT) for cutaneous head and neck carcinoma with perineural invasion (PNI), with the aim of developing risk-adapted treatment guidelines.

The pPNI and cPNI groups also differed in relapse-free survival (76% vs 46%, p = .003), disease-specific survival (90% vs 76%, p = .002), and overall survival (69% vs 57%, p = .03).

pPNI patients with BCC histology (n = 42) had better LC (97% vs 84%, p = .02) than pPNI SCC (n = 55).

CONCLUSION: Surgery plus RT provides a high rate of LC in patients with pPNI, particularly those with BCC.

[MeSH-major] Carcinoma, Basal Cell / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / radiotherapy. Peripheral Nerves / pathology. Peripheral Nervous System Neoplasms / radiotherapy. Skin Neoplasms / radiotherapy

[MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Radiotherapy, Adjuvant. Retrospective Studies. Risk Assessment

MedlinePlus Health Information. consumer health - Head and Neck Cancer.

MedlinePlus Health Information. consumer health - Skin Cancer.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] Head Neck. 2009 Nov;31(11):1531; author reply 1532-3 [19787793.001]

(PMID = 19132719.001).

[ISSN] 1097-0347

[Journal-full-title] Head & neck

[ISO-abbreviation] Head Neck

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Presence of papillomavirus sequences in condylomatous lesions of the mamillae and in invasive carcinoma of the breast.

BACKGROUND: Viruses including Epstein-Barr virus (EBV), a human equivalent of murine mammary tumour virus (MMTV) and human papillomavirus (HPV) have been implicated in the aetiology of human breast cancer.

We report the presence of HPV DNA sequences in areolar tissue and tumour tissue samples from female patients with breast carcinoma.

The presence of virus in the areolar-nipple complex suggests to us a potential pathogenic mechanism.

METHODS: Polymerase chain reaction (PCR) was undertaken to amplify HPV types in areolar and tumour tissue from breast cancer cases.

RESULTS: Papillomavirus DNA was present in 25 of 29 samples of breast carcinoma and in 20 of 29 samples from the corresponding mamilla.

The most prevalent type in both carcinomas and nipples was HPV 11, followed by HPV 6.

Other types detected were HPV 16, 23, 27 and 57 (nipples and carcinomas), HPV 20, 21, 32, 37, 38, 66 and GA3-1 (nipples only) and HPV 3, 15, 24, 87 and DL473 (carcinomas only).

Multiple types were demonstrated in seven carcinomas and ten nipple samples.

CONCLUSIONS: The data demonstrate the occurrence of HPV in nipple and areolar tissues in patients with breast carcinoma.

[MeSH-major] Breast Neoplasms / virology. Carcinoma / virology. Nipples / virology. Papillomaviridae / genetics. Papillomaviridae / pathogenicity

MedlinePlus Health Information. consumer health - Breast Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Pathol Res Pract. 1992 Apr;188(3):384-6 [1320761.001]

[Cites] J Natl Cancer Inst. 2001 Jun 6;93(11):824-42 [11390532.001]

[Cites] Cancer Res. 1992 Nov 1;52(21):5872-8 [1327518.001]

[Cites] EMBO J. 1993 May;12(5):1847-52 [8387914.001]

[Cites] J Gen Virol. 1994 May;75 ( Pt 5):1157-62 [8176376.001]

[Cites] Curr Top Microbiol Immunol. 1994;186:1-12 [8205835.001]

[Cites] J Dermatol. 1994 Oct;21(10):709-15 [7798425.001]

[Cites] Proc Natl Acad Sci U S A. 1995 Aug 15;92(17):7829-33 [7644500.001]

[Cites] Virology. 1996 Jun 1;220(1):1-9 [8659100.001]

[Cites] Breast Cancer Res Treat. 1996;39(2):197-202 [8872328.001]

[Cites] Biochim Biophys Acta. 1996 Oct 9;1288(2):F55-78 [8876633.001]

[Cites] Breast Cancer Res Treat. 1996;41(1):51-7 [8932876.001]

[Cites] Cancer Epidemiol Biomarkers Prev. 1996 Dec;5(12):961-5 [8959317.001]

[Cites] J Gen Virol. 1995 Apr;76 ( Pt 4):1057-62 [9049358.001]

[Cites] Int J Cancer. 1997 Nov 4;73(3):356-61 [9359482.001]

[Cites] Mol Cell Biol. 1998 Apr;18(4):1793-801 [9528751.001]

[Cites] J Virol. 2001 Dec;75(23):11791-802 [11689660.001]

[Cites] Nat Rev Cancer. 2002 May;2(5):342-50 [12044010.001]

[Cites] J Hum Virol. 2001 Nov-Dec;4(6):329-34 [12082399.001]

[Cites] Int J Cancer. 2002 Jul 10;100(2):214-9 [12115572.001]

[Cites] J Virol. 2002 Oct;76(20):10559-68 [12239337.001]

[Cites] Lancet. 2002 Oct 5;360(9339):1044-9 [12383984.001]

[Cites] Int J Cancer. 2002 Nov 20;102(3):304-7 [12397656.001]

[Cites] Br J Cancer. 2002 Nov 18;87(11):1234-45 [12439712.001]

[Cites] Cancer. 2002 Dec 15;95(12):2571-6 [12467072.001]

[Cites] J Natl Cancer Inst. 2002 Dec 18;94(24):1832-6 [12488476.001]

[Cites] J Virol. 2003 Jan;77(2):1551-63 [12502868.001]

[Cites] J Med Virol. 2004 Mar;72(3):473-7 [14748072.001]

[Cites] Int J Cancer. 2004 Mar 20;109(2):253-8 [14750177.001]

[Cites] Breast Cancer Res Treat. 2004 Mar;84(2):131-7 [14999143.001]

[Cites] Int J Cancer. 1982 Feb 15;29(2):143-6 [6277807.001]

[Cites] Int J Cancer. 1985 Nov 15;36(5):575-8 [2997044.001]

[Cites] J Virol. 1986 Jan;57(1):353-6 [3001357.001]

[Cites] J Virol. 1986 Jun;58(3):963-6 [3009899.001]

[Cites] Cancer. 1987 Oct 15;60(8):1832-5 [2820563.001]

[Cites] Virology. 1988 Jul;165(1):225-33 [2838960.001]

[Cites] Virology. 1989 Nov;173(1):284-90 [2554574.001]

[Cites] Proc Natl Acad Sci U S A. 1990 Jan;87(1):463-7 [2153303.001]

[Cites] Br J Dermatol. 1990 Jun;122(6):757-62 [2164414.001]

[Cites] Am J Clin Pathol. 1991 Feb;95(2):117-24 [1846996.001]

[Cites] Virology. 1991 Nov;185(1):484-7 [1656601.001]

[Cites] Br J Cancer. 1992 Jun;65(6):891-4 [1319728.001]

[Cites] J Invest Dermatol. 1998 May;110(5):752-5 [9579540.001]

[Cites] Laryngoscope. 1998 May;108(5):735-40 [9591556.001]

[Cites] Biomed Pharmacother. 1998;52(1):26-33 [9755792.001]

[Cites] Int J Cancer. 1999 Mar 1;80(5):681-4 [10048966.001]

[Cites] Int J Cancer. 1999 Apr 12;81(2):225-8 [10188723.001]

[Cites] Breast Cancer Res Treat. 1999 Jan;53(2):121-35 [10326789.001]

[Cites] Oncogene. 1999 Apr 1;18(13):2201-11 [10327066.001]

[Cites] J Gen Virol. 1999 Jun;80 ( Pt 6):1513-7 [10374970.001]

[Cites] J Virol. 1999 Sep;73(9):7297-307 [10438818.001]

[Cites] J Natl Cancer Inst. 1999 Aug 18;91(16):1349-50 [10451431.001]

[Cites] J Gen Virol. 1999 Sep;80 ( Pt 9):2437-43 [10501499.001]

[Cites] J Exp Clin Cancer Res. 1999 Sep;18(3):369-77 [10606184.001]

[Cites] Semin Cancer Biol. 1999 Dec;9(6):413-22 [10712888.001]

[Cites] J Biol Chem. 2000 May 19;275(20):14824-30 [10809724.001]

[Cites] Cancer Epidemiol Biomarkers Prev. 2000 Jul;9(7):697-703 [10919740.001]

[Cites] Breast Cancer. 2000 Jan;7(1):33-6 [11029768.001]

[Cites] J Virol. 2000 Dec;74(24):11636-41 [11090162.001]

[Cites] J Virol. 2001 Jan;75(1):151-60 [11119584.001]

[Cites] Arch Virol. 2001;146(1):171-80 [11266212.001]

[Cites] Anticancer Res. 2001 Jan-Feb;21(1B):797-801 [11299846.001]

[Cites] Breast Cancer Res Treat. 1992;21(2):95-100 [1320958.001]

(PMID = 15642157.001).

[ISSN] 1465-542X

[Journal-full-title] Breast cancer research : BCR

[ISO-abbreviation] Breast Cancer Res.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / DNA, Viral

[Other-IDs] NLM/ PMC1064094

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Metaplastic breast cancer: clinical significance.

BACKGROUND: Metaplastic breast carcinoma (MBC) is a rare poorly differentiated breast cancer characterized by coexistence of ductal carcinoma with areas of matrix producing, spindle-cell, sarcomatous, or squamous differentiation; ER/PR/HER2 negativity; and a reputation for poor outcome.

METHODS: The Swedish Cancer Institute prospective breast cancer database (> 6500 patients; 1990-2005) has 24 MBC cases that were compared with typical breast cancer cases matched for age, date of diagnosis, stage, and ER/PR/HER2 status.

The histological/nuclear grade was high in 21 of 24 cases.

ER and/or PR receptor status was negative in all cases.

HER2 was negative in 10 of 11 cases tested.

EGFR (HER1) was positive in 7 of 7 cases tested.

Four patients had distant recurrences 5 to 88 months from diagnosis.

Comparison with matched typical breast cancer cases revealed no major significant difference in multidisciplinary treatment patterns, recurrence, or survival.

CONCLUSION: MBC is associated with poor prognostic indicators, but outcomes comparable with matched typical breast cancer cases can be achieved with routine aggressive multidisciplinary care.

[MeSH-major] Breast Neoplasms / pathology

[MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Middle Aged. Neoplasm Metastasis. Prospective Studies. Risk Factors. Survival Rate. Sweden / epidemiology

Genetic Alliance. consumer health - Breast Cancer.

MedlinePlus Health Information. consumer health - Breast Cancer.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16647355.001).

[ISSN] 0002-9610

[Journal-full-title] American journal of surgery

[ISO-abbreviation] Am. J. Surg.

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] An unusual composite pilomatrix carcinoma with intralesional melanocytes: differential diagnosis, immunohistochemical evaluation, and review of the literature.

We report a case of an extremely rare histologic combination of pilomatrix or pilomatrical carcinoma with admixed melanocytes within the same tumor mass.

Pilomatrix carcinoma is a neoplasm of low-grade malignancy that is characterized by a tendency for recurrence but low risk of metastasis.

In addition, intermingled with the pilomatrix carcinoma, several easily identified pigmented cells with dendritic processes were present singly and as small aggregates.

Pilomatrix carcinoma with melanocytes should be distinguished from the conventional pilomatrixoma with pigmentation, melanocytic matricoma, melanoma, and pigmented basal cell carcinoma with matrical differentiation.

Clinicians and pathologists should be aware of the occurrence of pilomatrix carcinoma with melanocytes because of its potential for diagnosis as melanoma.

It is possible that sun damage played a role in stimulating migration of melanocytes among matrical cells in this case.

[MeSH-major] Carcinoma, Skin Appendage / pathology. Hair Diseases / pathology. Melanocytes / pathology. Pilomatrixoma / pathology. Skin Neoplasms / pathology

[MeSH-minor] Aged. Biopsy, Needle. Diagnosis, Differential. Follow-Up Studies. Humans. Immunohistochemistry. Male. Neoplasm Staging. Nose. Risk Assessment. Treatment Outcome

MedlinePlus Health Information. consumer health - Hair Problems.

MedlinePlus Health Information. consumer health - Skin Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18360125.001).

[ISSN] 1533-0311

[Journal-full-title] The American Journal of dermatopathology

[ISO-abbreviation] Am J Dermatopathol

[Language] eng

[Publication-type] Case Reports; Journal Article; Review

[Publication-country] United States

[Number-of-references] 30

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] CCHCR1 is up-regulated in skin cancer and associated with EGFR expression.

Despite chronic inflammation, psoriatic lesions hardly ever progress to skin cancer.

As CCHCR1 is expressed in certain cancers and regulates keratinocyte (KC) proliferation in a transgenic mouse model, we studied its relation to proliferation in cutaneous squamous cell cancer (SCC) cell lines by expression arrays and quantitative RT-PCR and in skin tumors by immunohistochemistry.

CCHCR1 protein was detected in the pushing border of SCC and lining basal cell carcinoma islands.

The most aggressive and invasive tumor cell lines (RT3, FaDu) expressed CCHCR1 mRNA less than non-tumorigenic HaCaT cells.

[MeSH-major] Gene Expression Regulation, Neoplastic. Intracellular Signaling Peptides and Proteins / genetics. Intracellular Signaling Peptides and Proteins / physiology. Psoriasis / metabolism. Receptor, Epidermal Growth Factor / biosynthesis. Skin Neoplasms / metabolism. Up-Regulation

[MeSH-minor] Cell Line, Tumor. Cell Proliferation. Humans. Immunohistochemistry / methods. Inflammation. Ki-67 Antigen / biosynthesis. Lymphocytes / metabolism. Models, Biological. Reverse Transcriptase Polymerase Chain Reaction

MedlinePlus Health Information. consumer health - Psoriasis.

MedlinePlus Health Information. consumer health - Skin Cancer.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Oncogene. 2007 Aug 9;26(36):5267-79 [17334397.001]

[Cites] J Mol Med (Berl). 2007 Jun;85(6):589-601 [17221218.001]

[Cites] Am J Pathol. 2008 Jul;173(1):14-24 [18556782.001]

[Cites] J Invest Dermatol. 2009 Jan;129(1):119-30 [18633436.001]

[Cites] Hum Exp Toxicol. 1999 Oct;18(10):634-9 [10557016.001]

[Cites] Hum Mol Genet. 2000 Jun 12;9(10):1533-42 [10888604.001]

[Cites] J Cutan Pathol. 2001 Feb;28(2):57-64 [11168753.001]

[Cites] Arch Dermatol Res. 2001 Apr;293(4):206-13 [11380154.001]

[Cites] Gene. 2001 Jul 25;273(1):1-11 [11483355.001]

[Cites] Hum Mol Genet. 2002 Mar 1;11(5):589-97 [11875053.001]

[Cites] J Invest Dermatol. 2002 May;118(5):759-66 [11982752.001]

[Cites] Arch Dermatol Res. 2002 Jul;294(5):243-5 [12115028.001]

[Cites] J Biol Chem. 2002 Oct 11;277(41):38965-71 [12181310.001]

[Cites] FEBS Lett. 2003 Jul 17;547(1-3):15-9 [12860379.001]

[Cites] J Invest Dermatol. 2003 Dec;121(6):1360-4 [14675183.001]

[Cites] Lab Invest. 2003 Dec;83(12):1887-99 [14691307.001]

[Cites] Cancer Res. 2004 Jun 1;64(11):3934-9 [15173005.001]

[Cites] Hum Mol Genet. 2004 Aug 1;13(15):1551-61 [15190014.001]

[Cites] Arch Dermatol. 2004 Jul;140(7):805-10 [15262690.001]

[Cites] FASEB J. 2004 Aug;18(11):1252-4 [15208259.001]

[Cites] Acta Derm Venereol. 2004;84(4):308-9 [15339078.001]

[Cites] Cell. 1980 Jan;19(1):245-54 [6153576.001]

[Cites] J Cell Biol. 1988 Mar;106(3):761-71 [2450098.001]

[Cites] Cell Growth Differ. 1994 Nov;5(11):1205-13 [7848922.001]

[Cites] J Biol Chem. 1995 Nov 10;270(45):27136-42 [7592968.001]

[Cites] Semin Cancer Biol. 1995 Aug;6(4):239-48 [8541519.001]

[Cites] Biochem Biophys Res Commun. 1996 Nov 12;228(2):586-95 [8920955.001]

[Cites] J Biol Chem. 1999 Jan 8;274(2):1124-30 [9873060.001]

[Cites] Matrix Biol. 1998 Dec;17(8-9):547-57 [9923649.001]

[Cites] Nature. 2004 Nov 18;432(7015):324-31 [15549094.001]

[Cites] Br J Dermatol. 2005 Jun;152(6):1248-55 [15948989.001]

[Cites] J Cell Sci. 2005 Sep 15;118(Pt 18):4253-60 [16141233.001]

[Cites] Carcinogenesis. 2006 Feb;27(2):225-31 [16123117.001]

[Cites] FEBS Lett. 2006 Mar 20;580(7):1859-64 [16516204.001]

[Cites] Int J Biochem Cell Biol. 2006;38(7):1043-9 [16423552.001]

[Cites] Br J Dermatol. 2006 Jul;155(1):213-4 [16792781.001]

[Cites] Exp Dermatol. 2006 Oct;15(10):775-83 [16984259.001]

[Cites] J Investig Dermatol Symp Proc. 2006 Sep;11(1):16-29 [17069007.001]

[Cites] Steroids. 2007 Feb;72(2):210-7 [17173942.001]

[Cites] Am J Pathol. 2007 Jun;170(6):2089-99 [17525275.001]

[Cites] Hum Mol Genet. 2008 Apr 1;17(7):1043-51 [18174193.001]

(PMID = 19551138.001).

[ISSN] 1932-6203

[Journal-full-title] PloS one

[ISO-abbreviation] PLoS ONE

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / CCHCR1 protein, human; 0 / Intracellular Signaling Peptides and Proteins; 0 / Ki-67 Antigen; EC 2.7.10.1 / Receptor, Epidermal Growth Factor

[Other-IDs] NLM/ PMC2696036

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Mutational profile of the CAV-1 gene in breast cancer cases in the ethnic Kashmiri population.

The role of caveolae and the caveolin proteins in cancer has been the subject of extensive research.

It has been suggested that Caveolin-1 may contribute to certain steps of carcinogenesis in various types of cancer.

Therefore in our study we focused on the potential clinical relevance of Caveolin-1 in 130 malignant breast tissue specimens along with their adjacent normal tissues.

Caveolin-1 was identified in a screen for genes involved in breast cancer progression and we demonstrated 29.2% mutational status in our Kashmiri ethnic population.

[MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms, Male / genetics. Caveolin 1 / genetics

Genetic Alliance. consumer health - Breast Cancer.

MedlinePlus Health Information. consumer health - Breast Cancer.

MedlinePlus Health Information. consumer health - Male Breast Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 21133631.001).

[ISSN] 2476-762X

[Journal-full-title] Asian Pacific journal of cancer prevention : APJCP

[ISO-abbreviation] Asian Pac. J. Cancer Prev.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Thailand

[Chemical-registry-number] 0 / Caveolin 1; 0 / Codon, Nonsense

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Basal cell carcinoma: analysis of regression after incomplete excision.

[MeSH-major] Carcinoma, Basal Cell / surgery. Skin Neoplasms / surgery

[MeSH-minor] Female. Humans. Male. Neoplasm Regression, Spontaneous. Neoplasm, Residual. Reoperation

MedlinePlus Health Information. consumer health - Skin Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19686288.001).

[ISSN] 1365-2230

[Journal-full-title] Clinical and experimental dermatology

[ISO-abbreviation] Clin. Exp. Dermatol.

[Language] eng

[Publication-type] Letter

[Publication-country] England

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Current recommendations in the treatment of basal cell carcinoma and squamous cell carcinoma of the skin].

[Transliterated title] Aktuelle Therapieempfehlungen für das Basalzellkarzinom und Plattenepithelkarzinom der Haut.

The incidence of the most common tumors of the skin, basal cell carcinoma and squamous cell carcinoma, has risen rapidly in recent years.

[MeSH-major] Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Facial Neoplasms / surgery. Skin Neoplasms / surgery

[MeSH-minor] Combined Modality Therapy. Humans. Neoplasm Invasiveness. Neoplasm, Residual / pathology. Neoplasm, Residual / radiotherapy. Neoplasm, Residual / surgery. Prognosis. Radiotherapy, Adjuvant. Skin / pathology. Surgical Flaps

Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

MedlinePlus Health Information. consumer health - Skin Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Strahlenther Onkol. 2001 May;177(5):240-6 [11398609.001]

[Cites] Facial Plast Surg. 1997 Apr;13(2):79-82 [9243982.001]

[Cites] Hautarzt. 2005 May;56(5):430-40 [15815888.001]

[Cites] J Am Acad Dermatol. 2004 May;50(5):722-33 [15097956.001]

[Cites] J Dermatol Surg Oncol. 1994 May;20(5):350 [8176049.001]

[Cites] Recent Results Cancer Res. 2002;160:219-24 [12079216.001]

[Cites] Cancer. 1997 Mar 1;79(5):915-9 [9041153.001]

[Cites] BMJ. 2004 Sep 25;329(7468):705 [15364703.001]

[Cites] Dermatol Surg. 2000 Aug;26(8):759-64 [10940063.001]

[Cites] Br J Dermatol. 2000 Apr;142(4):752-7 [10792227.001]

[Cites] Int J Cancer. 1999 May 17;81(4):555-9 [10225444.001]

[Cites] Acta Derm Venereol. 2004;84(3):218-22 [15202839.001]

[Cites] J Am Acad Dermatol. 2007 Jan;56(1):91-5 [17190625.001]

[Cites] Br J Dermatol. 2006 Jun;154(6):1202-3 [16704658.001]

[Cites] Lancet. 1988 Apr 9;1(8589):795-7 [2895318.001]

[Cites] Dermatol Surg. 2006 Nov;32(11):1309-21 [17083582.001]

[Cites] J Eur Acad Dermatol Venereol. 2006 Sep;20(8):926-30 [16922939.001]

[Cites] J Dtsch Dermatol Ges. 2006 Mar;4(3):260-2 [16626324.001]

[Cites] J Dermatol Surg Oncol. 1991 Jul;17(7):574-8 [1860987.001]

[Cites] Br J Cancer. 1997;76(1):100-6 [9218740.001]

[Cites] Arch Dermatol. 2004 Oct;140(10 ):1286-7 [15492202.001]

[Cites] Hautarzt. 1975 Dec;26(12):647-50 [1213885.001]

[Cites] Dermatol Surg. 2004 Apr;30(4 Pt 2):642-50 [15061849.001]

[Cites] J Dtsch Dermatol Ges. 2006 May;4(5):441-3 [16686614.001]

[Cites] Hautarzt. 1995 Sep;46(9):607-14 [7591764.001]

[Cites] J Am Acad Dermatol. 2007 Jan;56(1):125-43 [17190630.001]

[Cites] J Am Acad Dermatol. 2003 Sep;49(3):483-6 [12963913.001]

[Cites] Eur J Dermatol. 2002 Nov-Dec;12 (6):569-72 [12459530.001]

[Cites] Br J Dermatol. 2002 Dec;147(6):1227-36 [12452875.001]

[Cites] Recent Results Cancer Res. 2002;160:240-5 [12079219.001]

(PMID = 17443305.001).

[ISSN] 0017-8470

[Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete

[ISO-abbreviation] Hautarzt

[Language] ger

[Publication-type] English Abstract; Journal Article; Review

[Publication-country] Germany

[Number-of-references] 31

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Cutaneous squamous carcinoma in situ (Bowen's disease): treatment with Mohs micrographic surgery.

BACKGROUND: Bowen's disease (BD), also known as squamous intraepidermal carcinoma, is a malignant skin tumor with a potential to progress to invasive carcinoma.

METHODS: This prospective, multicenter, case series included all patients in Australia treated with MMS for BD, who were monitored by the Skin and Cancer Foundation between 1993 and 2002.

RESULTS: There were 270 cases; the majority (93.4%) were located in the head and neck area.

In 50.7% of cases it was a recurrent tumor.

In 20% the tumor was initially misdiagnosed as basal cell carcinoma or squamous cell carcinoma.

No cases with perineural invasion were diagnosed.

There were 6 cases of recurrence (6.3%) of 95 patients who completed a 5-year follow-up period after MMS.

[MeSH-major] Bowen's Disease / surgery. Mohs Surgery. Skin Neoplasms / surgery

Genetic Alliance. consumer health - Bowen's Disease.

MedlinePlus Health Information. consumer health - Skin Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15928618.001).

[ISSN] 1097-6787

[Journal-full-title] Journal of the American Academy of Dermatology

[ISO-abbreviation] J. Am. Acad. Dermatol.

[Language] eng

[Publication-type] Clinical Trial; Journal Article; Multicenter Study

[Publication-country] United States

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Macrophage responses to CF pathogens: JNK MAP kinase signaling by Burkholderia cepacia complex lipopolysaccharide.

Burkholderia cepacia complex (Bcc) organisms pose a particular challenge in CF lung disease, due in part to their ability to trigger a fulminant pneumonia.

This study compares the U937 macrophage response to two Bcc species, B. cenocepacia and Burkholderia multivorans, against Pseudomonas aeruginosa and Staphylococcus aureus.

The two Bcc strains demonstrated higher levels of U937 macrophage internalization compared with both P. aeruginosa and S. aureus.

Both the Bcc strains also stimulated significantly greater levels of tumor necrosis factor-α and interleukin-1β from macrophages when compared with P. aeruginosa.

Further examination of the macrophage response to B. multivorans demonstrated that the lipopolysaccharide component of these bacteria was a potent inducer of proinflammatory cytokines and was shown to signal predominantly through the c-Jun N-terminal kinase mitogen-activated protein kinase pathway.

These studies further characterize the host response to Bcc and in particular B. multivorans, now the predominant Bcc species in many CF populations.

[MeSH-major] Burkholderia cepacia complex / immunology. Cytokines / secretion. JNK Mitogen-Activated Protein Kinases / metabolism. Lipopolysaccharides / immunology. Macrophages / immunology. Signal Transduction

[MeSH-minor] Cell Line. Cytoplasm / microbiology. Humans. Pseudomonas aeruginosa / immunology. Staphylococcus aureus / immunology

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] © 2010 Federation of European Microbiological Societies. Published by Blackwell Publishing Ltd. All rights reserved.

(PMID = 20602636.001).

[ISSN] 1574-695X

[Journal-full-title] FEMS immunology and medical microbiology

[ISO-abbreviation] FEMS Immunol. Med. Microbiol.

[Language] eng

[Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Cytokines; 0 / Lipopolysaccharides; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Surgical oophorectomy for breast cancer: back to the future.

While the preponderance of current scientific presentations on breast cancer therapies has focused on chemotherapeutic strategies, targeted therapy with tyrosine kinase inhibitors and hormonal therapies for postmenopausal women, the majority of worldwide cases of breast cancer occur in premenopausal women, for whom practical inexpensive hormonal therapy, surgical oophorectomy, is the most common attainable treatment.

In hormone-receptor-positive breast cancer, meta-analysis data from older trials, and more specific recent trial data have made clearer the chronic natural history of this broad subtype of disease and the central role of hormonal therapy in its control.

Greater understanding of the critical variables in pathology procedures for breast tumor tissue hormonal receptor testing is leading to better definitions of the specific patients for whom hormonal therapies are indicated.

Closer examination of outcomes following surgical oophorectomy has suggested that more than just downregulation of estrogen stimulated breast cancer growth; the reduction of systemic estrogen levels also occurs with this procedure.

This combination of circumstances suggests that this first hormonal therapy for breast cancer may once again, have a much greater role globally.

[MeSH-major] Breast Neoplasms / surgery. Ovariectomy

Genetic Alliance. consumer health - Breast Cancer.

MedlinePlus Health Information. consumer health - Breast Cancer.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. TAMOXIFEN .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19086845.001).

[ISSN] 1744-8301

[Journal-full-title] Future oncology (London, England)

[ISO-abbreviation] Future Oncol

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] England

[Chemical-registry-number] 0 / Estrogen Antagonists; 0 / Receptors, Estrogen; 094ZI81Y45 / Tamoxifen

[Number-of-references] 44

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Gene-environment interactions in breast cancer.

Breast cancer is one of the most frequently diagnosed cancers in women.

It accounts for 23% of all cancers, with an estimated 1.15 million new cases in 2002.

Breast cancers also tend to cluster in families and are more common in monozygotic twins.

Some of this clustering occurs as part of specific familial breast cancer syndromes where disease results from single alleles conferring a high risk.

However, such alleles are rare in the population, and highly penetrant variants of BRCA1 and BRCA2 account for less than 20% of the genetic risk of breast cancer.

The more common sporadic form of breast cancer are probably due to a polygenic inheritance of breast cancer susceptibility upon which environmental factors act upon resulting in breast cancer occurrence.

The lack of large prospective cohorts with thousands of incident breast cancer cases makes the study of gene-environment interactions using a nested case-control design extremely difficult.

[MeSH-major] Breast Neoplasms / etiology. Environment. Genes / physiology

[MeSH-minor] Female. Genetic Predisposition to Disease. Humans. Risk Factors

Genetic Alliance. consumer health - Breast Cancer.

MedlinePlus Health Information. consumer health - Breast Cancer.

MedlinePlus Health Information. consumer health - Genes and Gene Therapy.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18972750.001).

[ISSN] 1528-2511

[Journal-full-title] Novartis Foundation symposium

[ISO-abbreviation] Novartis Found. Symp.

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] England

[Number-of-references] 32

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Study of BRCA1 and BRCA2 gene mutations in human sporadic breast cancers].

OBJECTIVE: To detect the mutations of BRCA1 and BRCA2 in sporadic breast cancer and study the relationship between BRCA1 and BRCA2 mutations and breast cancer.

METHODS: Breast cancer tissues of 144 patients and breast tissues of 30 cases of healthy people who were treated from December 2000 to September 2005 were studied.

RESULTS: A total of 20 single nucleotide changes in BRCA1 were detected in the 144 cases of breast cancer patients.

CONCLUSIONS: Mutations in BRCA1 may play an important role in evaluation of sick risk, earlier diagnosis and gene therapy of breast cancer in southern Chinese populations.

[MeSH-major] BRCA1 Protein / genetics. BRCA2 Protein / genetics. Breast Neoplasms / genetics. Mutation

MedlinePlus Health Information. consumer health - Breast Cancer.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17686308.001).

[ISSN] 0529-5815

[Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]

[ISO-abbreviation] Zhonghua Wai Ke Za Zhi

[Language] chi

[Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] China

[Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / BLID protein, human; 0 / BRCA1 Protein; 0 / BRCA1 protein, human; 0 / BRCA2 Protein; 0 / BRCA2 protein, human

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Diet among breast cancer survivors and healthy women. The Norwegian Women and Cancer Study.

OBJECTIVE: To compare the diet and lifestyle in breast cancer survivors and healthy women.

DESIGN: Cross-sectional study in the population-based Norwegian Women and Cancer cohort study, using a postal questionnaire on diet, lifestyle and health.

Prevalent breast cancer cases (314 short-term with 1-5 years since diagnosis, 352 long-term with >5 years since diagnosis) were identified by linkage to the Norwegian Cancer Registry.

Short-term breast cancer survivors also had a higher use of dietary supplements and a lower level of physical activity, but did not differ from healthy women on other lifestyle factors.

CONCLUSION: Diet and lifestyle is generally similar between breast cancer survivors and healthy women, especially more than 5 years after diagnosis.

[MeSH-major] Breast Neoplasms / psychology. Diet Surveys. Food Habits / psychology. Health Status. Life Style

Genetic Alliance. consumer health - Breast Cancer.

MedlinePlus Health Information. consumer health - Breast Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Published online 15 February 2006.

(PMID = 16482067.001).

[ISSN] 0954-3007

[Journal-full-title] European journal of clinical nutrition

[ISO-abbreviation] Eur J Clin Nutr

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] England

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Race/ethnicity and changing US socioeconomic gradients in breast cancer incidence: California and Massachusetts, 1978-2002 (United States).

OBJECTIVE: We tested the hypothesis that the US socioeconomic gradient in breast cancer incidence is declining, with the decline most pronounced among racial/ethnic groups with the highest incidence rates.

METHODS: We geocoded the invasive incident breast cancer cases for three US population-based cancer registries covering: Los Angeles County, CA (1978-1982, 1988-1992, 1998-2002; n = 68,762 cases), the San Francisco Bay Area, CA (1978-1982, 1988-1992, 1998-2002; n = 37,210 cases) and Massachusetts (1988-1992, 1998-2002; n = 48,111 cases), linked the records to census tract area-based socioeconomic measures, and, for each socioeconomic stratum, computed average annual breast cancer incidence rates for the 5-year period straddling the 1980, 1990, and 2000 census, overall and by race/ethnicity and gender.

RESULTS: Our findings indicate that the socioeconomic gradient in breast cancer incidence is: (a) relatively small (at most 1.2) and stable among US white non-Hispanic and black women;.

CONCLUSION: Our results indicate that secular changes in US socioeconomic gradients in breast cancer incidence exist and vary by race/ethnicity.

[MeSH-major] Breast Neoplasms / epidemiology

Genetic Alliance. consumer health - Breast Cancer.

MedlinePlus Health Information. consumer health - Breast Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16425100.001).

[ISSN] 0957-5243

[Journal-full-title] Cancer causes & control : CCC

[ISO-abbreviation] Cancer Causes Control

[Language] eng

[Grant] United States / NCI NIH HHS / PC / N01-PC-35139; United States / NCI NIH HHS / CA / R01 CA095983-01

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] Netherlands

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Naphthenic acids are a complex family of naturally occurring cyclic and acyclic carboxylic acids that are present in the acidic fraction of petroleum.

In contrast, cluster diagrams produced from the denaturing gradient gel electrophoresis data clearly separated bacterial communities according to naphthenic acids concentrations, indicating that naphthenic acids content was a major influence on the composition of the bacterial community.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. NAPHTHENIC ACIDS .

Hazardous Substances Data Bank. NAPHTHENIC ACIDS, LEAD SALTS .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16420616.001).

[ISSN] 0168-6496

[Journal-full-title] FEMS microbiology ecology

[ISO-abbreviation] FEMS Microbiol. Ecol.

[Language] eng

[Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Netherlands

[Chemical-registry-number] 0 / Carboxylic Acids; 0 / DNA, Bacterial; 0 / Fatty Acids; 0 / Industrial Waste; 0 / Petroleum; 0 / Reagent Kits, Diagnostic; 1338-24-5 / naphthenic acid

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Comparison of male and female breast cancer incidence trends, tumor characteristics, and survival.

PURPOSE: To compare male and female breast cancer and to determine the predictors of tumor characteristics and survival in both genders.

METHODS: Male (n = 2923) and female breast cancer cases (n = 442,500) from the Surveillance, Epidemiology and End Results (SEER) registry were analyzed.

Cox proportional hazards regression modeling was used to determine significant predictors of death of breast cancer after adjusting for demographic factors.

RESULTS: Both men and women aged less than 50 years were at higher risk for advanced breast cancers.

The risk of breast cancer death among all cases was lower for each 10-year increase in age by 2%, higher for those who are unmarried than for those who are married by 12% and 13% higher for non-whites than for whites.

[MeSH-major] Breast Neoplasms / epidemiology. Breast Neoplasms / pathology. Breast Neoplasms, Male / epidemiology. Breast Neoplasms, Male / pathology. SEER Program / statistics & numerical data

[MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Functional Laterality. Humans. Incidence. Male. Middle Aged. Neoplasm Staging. Prognosis. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Regression Analysis. Risk Factors. Sex Factors. Survival

Genetic Alliance. consumer health - Breast Cancer.

Genetic Alliance. consumer health - Breast Cancer, Male.

MedlinePlus Health Information. consumer health - Breast Cancer.

MedlinePlus Health Information. consumer health - Male Breast Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16257362.001).

[ISSN] 1047-2797

[Journal-full-title] Annals of epidemiology

[ISO-abbreviation] Ann Epidemiol

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Phosphorylated human lectin galectin-3: analysis of ligand binding by histochemical monitoring of normal/malignant squamous epithelia and by isothermal titration calorimetry.

We monitored normal and malignant squamous epithelia.

Basal cell carcinomas were invariably negative.

In all cases, binding was inhibitable by the presence of lactose, prompting further investigation of the activity of the lectin site by a sensitive biochemical method, i.e. isothermal titration calorimetry.

[MeSH-major] Epithelial Cells / chemistry. Epithelium / metabolism. Galectin 3 / metabolism. Neoplasms, Squamous Cell / metabolism. Phosphorylation

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18983621.001).

[ISSN] 1439-0264

[Journal-full-title] Anatomia, histologia, embryologia

[ISO-abbreviation] Anat Histol Embryol

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Germany

[Chemical-registry-number] 0 / Galectin 3

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Cytogenetics of melanoma and nonmelanoma skin cancer.

Cytogenetic analysis of melanoma and nonmelanoma skin cancers has revealed recurrent aberrations, the frequency of which is reflective of malignant potential.

Highly aberrant karyotypes are seen in melanoma, squamous cell carcinoma, solar keratosis and Merkel cell carcinoma with more stable karyotypes seen in basal cell carcinoma, keratoacanthoma, Bowen's disease, dermatofibrosarcoma protuberans and cutaneous lymphomas.

Some aberrations were common amongst a number of skin cancer types including rearrangements and numerical abnormalities of chromosome 1, -3p, +3q, partial or entire trisomy 6, trisomy 7, +8q, -9p, +9q, partial or entire loss of chromosome 10, -17p, +17q and partial or entire gain of chromosome 20.

Combination of cytogenetic analysis with other molecular genetic techniques has enabled the identification of not only aberrant chromosomal regions, but also the genes that contribute to a malignant phenotype.

This review provides a comprehensive summary of the pertinent cytogenetic aberrations associated with a variety of melanoma and nonmelanoma skin cancers.

[MeSH-major] Chromosome Aberrations. Cytogenetics. Melanoma / genetics. Skin Neoplasms / genetics

MedlinePlus Health Information. consumer health - Melanoma.

MedlinePlus Health Information. consumer health - Skin Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18348460.001).

[ISSN] 0065-2598

[Journal-full-title] Advances in experimental medicine and biology

[ISO-abbreviation] Adv. Exp. Med. Biol.

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Number-of-references] 104

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Polymorphisms in RAI and in genes of nucleotide and base excision repair are not associated with risk of testicular cancer.

Testicular cancer has been suggested to be primed in utero and there is familiar occurrence, particularly brothers and sons of men with testicular cancer have increased risk.

Although no specific causative genotoxic agents have been identified, variations in DNA repair capacity could be associated with the risk of testicular cancer.

A case-control study of 184 testicular cancer cases and 194 population-based controls living in the Copenhagen Greater Area in Denmark was performed.

We found that neither polymorphisms in several DNA repair genes nor alleles of several polymorphisms in the chromosomal of region 19q13.2-3, encompassing the genes ASE, ERCC1, RAI and XPD, were associated with risk of testicular cancer in Danish patients.

This is in contrast to other cancers, where we reported strong associations between polymorphisms in ERCC1, ASE and RAI and occurrence of basal cell carcinoma, breast cancer and lung.

To our knowledge this is the first study of DNA repair gene polymorphisms and risk of testicular cancer.

[MeSH-minor] Case-Control Studies. Denmark. Genetic Predisposition to Disease / genetics. Humans. Male. Repressor Proteins

Genetic Alliance. consumer health - Testicular cancer.

MedlinePlus Health Information. consumer health - Testicular Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15885892.001).

[ISSN] 0304-3835

[Journal-full-title] Cancer letters

[ISO-abbreviation] Cancer Lett.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Ireland

[Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / Nucleotides; 0 / PPP1R13L protein, human; 0 / Repressor Proteins

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Clinical trials published after the consensus conference (ACC; from 1993 to 2001) were compared with trials published before the consensus conference (BCC; from 1976 to 1992).

RESULTS: We identified 176 clinical trials (ACC, 119 trials; BCC, 57 trials).

The utilization of specified values for WBC count, temperature (T), heart rate (HR), and respiratory rate (RR) was significantly increased in the ACC group compared to the BCC group, as follows: WBC count, 62% vs 26%, respectively (p < 0.001); T, 89% vs 56%, respectively (p < 0.001); HR, 77% vs 26%, respectively (p < 0.001); and RR, respectively 76% vs 28% (p < 0.001).

(1) Since 1992 there has been a significant increase in the utilization of predefined sepsis criteria for patient enrollment in clinical trials, and this increase can be attributed to the existence of consensus conference definitions. (2) Compared to inclusion criteria BCC, inclusion criteria ACC were less reliant on blood culture positivity and were more likely to incorporate markers of organ dysfunction.

[MeSH-major] Clinical Trials as Topic / standards. Consensus Development Conferences as Topic. Patient Selection. Sepsis / diagnosis

MedlinePlus Health Information. consumer health - Clinical Trials.

MedlinePlus Health Information. consumer health - Sepsis.

COS Scholar Universe. author profiles.

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15653990.001).

[ISSN] 0012-3692

[Journal-full-title] Chest

[ISO-abbreviation] Chest

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The usefulness of electronic polarization in predicting hydration free energies is assessed by comparing the Electronic Polarization from Internal Continuum model and the self consistent reaction field IEF-PCM to standard non-polarizable charge models such as RESP and AM1-BCC.

Hazardous Substances Data Bank. GLUCOSE .

Hazardous Substances Data Bank. BENZENE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Phys Chem B. 2009 Apr 9;113(14):4501-7 [19338360.001]

[Cites] J Comput Chem. 2002 Dec;23(16):1623-41 [12395429.001]

[Cites] J Chem Theory Comput. 2009 Apr 14;5(4):919-30 [26609601.001]

[Cites] J Phys Chem B. 2008 Jan 24;112(3):938-46 [18171044.001]

[Cites] J Comput Chem. 2004 Jul 15;25(9):1157-74 [15116359.001]

[Cites] Biochim Biophys Acta. 2006 Nov;1764(11):1647-76 [17049320.001]

[Cites] J Chem Phys. 2007 Mar 7;126(9):094103 [17362100.001]

[Cites] J Chem Theory Comput. 2009 Jul 14;5(7):1785-1802 [24826083.001]

[Cites] Science. 1995 May 26;268(5214):1144-9 [7761829.001]

[Cites] J Chem Phys. 2007 Mar 28;126(12):124114 [17411115.001]

[Cites] J Chem Theory Comput. 2006 Jan;2(1):128-39 [26626387.001]

[Cites] J Chem Inf Model. 2007 Jan-Feb;47(1):122-33 [17238257.001]

[Cites] J Comput Chem. 2003 Jun;24(8):954-62 [12720316.001]

[Cites] J Med Chem. 2008 Feb 28;51(4):769-79 [18215013.001]

[Cites] Phys Rev A Gen Phys. 1988 Sep 15;38(6):3098-3100 [9900728.001]

[Cites] J Am Chem Soc. 2009 Oct 28;131(42):15403-11 [19778066.001]

[Cites] J Phys Chem B. 2009 Apr 9;113(14):4521-32 [19281198.001]

[Cites] J Comput Chem. 2004 Jan 30;25(2):265-84 [14648625.001]

[Cites] J Comput Chem. 2010 Mar;31(4):811-24 [19598266.001]

(PMID = 20354893.001).

[ISSN] 1573-4951

[Journal-full-title] Journal of computer-aided molecular design

[ISO-abbreviation] J. Comput. Aided Mol. Des.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Netherlands

[Chemical-registry-number] 0 / Solutions; 0 / Solvents; A1TA934AKO / Xylose; IY9XDZ35W2 / Glucose; J64922108F / Benzene

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Furthermore, the presence of these proteases at higher levels in SOKCs may help to explain increased OKC aggressiveness associated with nevoid basal cell carcinoma syndrome.

[MeSH-major] Basal Cell Nevus Syndrome / metabolism. Matrix Metalloproteinase 1 / biosynthesis. Matrix Metalloproteinase 7 / biosynthesis. Matrix Metalloproteinases, Secreted / biosynthesis. Odontogenic Cysts / enzymology

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18585626.001).

[ISSN] 1528-395X

[Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics

[ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 68238-35-7 / Keratins; EC 3.4.24.- / MMP26 protein, human; EC 3.4.24.- / Matrix Metalloproteinases, Secreted; EC 3.4.24.23 / Matrix Metalloproteinase 7; EC 3.4.24.7 / Matrix Metalloproteinase 1

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Nodular basal cell carcinoma: when in doubt, cut it out.

Treating superficial basal cell carcinomas (BCCs) with photodynamic therapy or topical imiquimod can provide effective results in situations where an excisional approach is contraindicated or undesirable.

Numerous studies have sought to test these treatments for nodular BCCs.

[MeSH-major] Carcinoma, Basal Cell / surgery. Skin Neoplasms / surgery

MedlinePlus Health Information. consumer health - Skin Cancer.

Hazardous Substances Data Bank. Imiquimod .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18189068.001).

[ISSN] 1545-9616

[Journal-full-title] Journal of drugs in dermatology : JDD

[ISO-abbreviation] J Drugs Dermatol

[Language] eng

[Publication-type] News

[Publication-country] United States

[Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid; 99011-02-6 / imiquimod

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Additionally, the production of short-chain fatty acids increased with 12%, 3% and 7%, while ammonia concentrations decreased with 3%, 4% and 3% in the ascending, transverse and descending colon compartments, respectively.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19200315.001).

[ISSN] 1365-2672

[Journal-full-title] Journal of applied microbiology

[ISO-abbreviation] J. Appl. Microbiol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / 7-hydroxy-5-methyl-3-phenyl-6,7,8,9-tetrahydropyrido(3',2'-4,5)imidazo(1,2-a)pyrimidin-5-ium; 0 / Fatty Acids, Volatile; 0 / Imidazoles; 0 / Mutagens; 0 / Prebiotics; 0 / Pyrimidines; 9005-80-5 / Inulin; 909C6UN66T / 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Impact of white-rot fungi on numbers and community composition of bacteria colonizing beech wood from forest soil.

White-rot fungi are important wood-decomposing organisms in forest ecosystems.

Their ability to colonize and decompose woody resources may be strongly influenced by wood-inhabiting bacteria that grow on easily utilizable compounds e.g. oligomers of wood-polymers released by fungal enzymes.

However, so far, it is not known how white-rot fungi deal with the presence of potential competing bacteria.

Here, the effects of two white-rot fungi, Hypholoma fasciculare and Resinicium bicolor, on the numbers and composition of bacteria colonizing sterile beech wood blocks from forest soil are reported.

Both total numbers (microscopic counts) and the numbers of cultivable wood-inhabiting bacteria were considerably lower in wood blocks that became colonized by the white-rot fungi than in control blocks.

This points to the fungi out-competing the opportunistic bacteria.

The presence of white-rot fungi resulted in a change in the relative abundance of families of cultivable bacteria in wood and also in a change of denaturing gradient gel electrophoresis patterns of directly amplified 16S rRNA gene fragments.

Analysis of the bacterial community structure in soil adhering to exploratory mycelium (cords) indicated that fungal species-specific effects on bacterial community composition were also apparent in this fungal growth phase.

[MeSH-major] Bacteria / isolation & purification. Basidiomycota. Soil Microbiology. Wood / microbiology

[MeSH-minor] Base Sequence. Colony Count, Microbial. Fagus / microbiology. Molecular Sequence Data. Phylogeny. RNA, Bacterial / genetics. RNA, Ribosomal, 16S / genetics. Sequence Analysis, RNA

SILVA. SILVA SSU Database .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18199083.001).

[ISSN] 0168-6496

[Journal-full-title] FEMS microbiology ecology

[ISO-abbreviation] FEMS Microbiol. Ecol.

[Language] eng

[Databank-accession-numbers] GENBANK/ EF027740/ EF027741/ EF027742/ EF027743/ EF027744/ EF027745/ EF027746/ EF027747/ EF027748/ EF027749/ EF027750/ EF027751/ EF027752/ EF027753/ EF027754/ EF027755/ EF027756/ EF027757/ EF027758/ EF027759/ EF027760/ EF027761/ EF027762/ EF027763/ EF027764/ EF027765/ EF027766/ EF027767/ EF027768/ EF027769/ EF027770/ EF027771/ EF027772/ EF027773/ EF027774/ EF027775/ EF027776/ EF027777/ EF027778/ EF027779/ EF027780/ EF027781/ EF027782/ EF027783/ EF027784/ EF027785/ EF027786/ EF027787/ EF027788/ EF027789/ EF027790/ EF027791/ EF027792/ EF027793/ EF027794/ EF027795/ EF027796/ EF027797/ EF027798/ EF027799/ EF027800/ EF027801/ EF027802/ EF027803/ EF027804/ EF027805/ EF027806/ EF027807/ EF027808/ EF027809/ EF027810/ EF027811/ EF027812/ EF027813/ EF027814/ EF027815/ EF027816/ EF027817/ EF027818/ EF027819/ EF027820/ EF027821/ EF027822/ EF027823/ EF027824/ EF027825/ EF027826/ EF027827/ EF027828/ EF027829/ EF027830/ EF027831/ EF027832/ EF027833/ EF027834/ EF027835/ EF027836/ EF027837/ EF027838/ EF027839/ EF027840/ EF027841/ EF027842/ EF027843/ EF027844/ EF027845/ EF027846/ EF027847/ EF027848/ EF027849/ EF027850/ EF027851/ EF027852/ EF027853/ EF027854/ EF027855/ EF027856/ EF027857/ EF027858

[Publication-type] Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / RNA, Bacterial; 0 / RNA, Ribosomal, 16S

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Co-expression and prognostic value of gross cystic disease fluid protein 15 and mammaglobin in primary breast cancer.

Gross cystic disease fluid protein (GCDFP-15) and mammaglobin are both widely used and accepted markers for epithelia of breast origin.

We aimed to evaluate their relation of expression on parallel whole tissue sections in primary breast cancer by immunohistochemistry and also to correlate it with clinico-pathological parameters including patient survival.

Primary breast carcinomas from 165 patients with a mean clinical follow-up of 73 months were immunostained using commercially available antibodies against GCDFP-15 and mammaglobin.

Cytoplasmic expression of GCDFP-15 and mammaglobin was observed in 73.3% and 72.1% of invasive breast carcinomas respectively.

91.8% of breast cancer cases expressed at least one of both markers.

Additionally, GCDFP-15 negativity was significantly associated with shortened disease-free survival times in univariate and multivariate analyses.

We demonstrated the strong correlation of GCDFP-15 and mammaglobin with each other and showed that only very few primary breast cancers are completely negative for both markers.

The significantly longer disease free survival times for patients with GCDFP-15 positive tumours clearly warrants further study.

[MeSH-major] Biomarkers, Tumor / metabolism. Breast Neoplasms / metabolism. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Lobular / metabolism. Carrier Proteins / metabolism. Glycoproteins / metabolism. Neoplasm Proteins / metabolism. Uteroglobin / metabolism

[MeSH-minor] Cell Count. Disease-Free Survival. Female. Humans. Mammaglobin A. Middle Aged. Survival Rate

Genetic Alliance. consumer health - Breast Cancer.

MedlinePlus Health Information. consumer health - Breast Cancer.

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17647195.001).

[ISSN] 1699-5848

[Journal-full-title] Histology and histopathology

[ISO-abbreviation] Histol. Histopathol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Spain

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Glycoproteins; 0 / Mammaglobin A; 0 / Neoplasm Proteins; 0 / PIP protein, human; 0 / SCGB2A2 protein, human; 9060-09-7 / Uteroglobin

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

In addition to the expected moderate reduction in plasma cholesterol levels, apoCIKO mice showed significant increases in the hepatic content of cholesteryl esters (+58%) and triglycerides (+118%) and in biliary cholesterol concentration (+35%) as compared with wild-type mice.

Biliary levels of cholesterol, phospholipids, and bile acids were increased by 88, 77, and 20%, respectively, whereas total cholesterol, HDL cholesterol, and triglyceride concentrations in plasma were further reduced in CETPTg/apoCIKO mice versus CETPTg mice.

In line with the previously recognized inhibition of lipoprotein clearance by apoC-I, apoC-I deficiency led to decreased plasma lipid concentration, hepatic lipid accumulation, and increased biliary excretion of cholesterol.

The effect was even greater when the alternate reverse cholesterol transport pathway via VLDL/LDL was boosted in the presence of CETP.

[MeSH-major] Apolipoprotein C-I / deficiency. Cholesterol Ester Transfer Proteins / metabolism. Lipids / physiology. Liver / metabolism

Jackson Laboratory JAX®Mice Database. culture/stock collections - B6.CBA-Tg(CETP)5203Tall/J (subscription/membership/fee required).

KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).

Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17053273.001).

[ISSN] 0022-2275

[Journal-full-title] Journal of lipid research

[ISO-abbreviation] J. Lipid Res.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Apolipoprotein C-I; 0 / Cholesterol Ester Transfer Proteins; 0 / Lipids; 63231-63-0 / RNA

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Photodynamic therapy for superficial basal cell carcinoma and Bowen's disease.

Photodynamic therapy (PDT) is an effective treatment for superficial basal cell carcinoma (BCCs) and Bowen's disease.

Bowen's disease and superficial basal cell carcinomas characteristically affect older patients who may also have associated difficulties with mobility.

[MeSH-major] Bowen's Disease / drug therapy. Carcinoma, Basal Cell / drug therapy. Photochemotherapy / methods. Skin Neoplasms / drug therapy

[MeSH-minor] Adult. Aged. Biopsy, Needle. Female. Great Britain / epidemiology. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Risk Assessment. Survival Rate. Treatment Outcome

Genetic Alliance. consumer health - Bowen's Disease.

MedlinePlus Health Information. consumer health - Skin Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16436340.001).

[ISSN] 1167-1122

[Journal-full-title] European journal of dermatology : EJD

[ISO-abbreviation] Eur J Dermatol

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] France

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] The effective treatment of basal cell carcinoma.

Basal cell carcinoma (BCC) accounts for 75% of all skin cancers and its incidence is rising by between 3-8% each year (Szeimies and Karrer, 2006).

As a result, the development of new therapeutic strategies and treatment methods for the removal of BCC is crucial in combating what is a growing problem.

The aim of this article is to critically review some of the current literature in order to substantiate the efficacy of destructive and non-surgical techniques as reliable alternatives to surgery for the management/removal of BCCs.

However, in relation to success rates, patients tolerance of the treatment and cosmetic outcomes, and depending on the type of BCC involved, other treatment methods do offer reliable alternatives.

[MeSH-major] Carcinoma, Basal Cell / therapy. Skin Neoplasms / therapy

[MeSH-minor] Adjuvants, Immunologic / therapeutic use. Administration, Cutaneous. Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Causality. Cryosurgery. Curettage. Great Britain / epidemiology. Humans. Incidence. Interferon-alpha / therapeutic use. Laser Therapy. Mohs Surgery. Neoplasm Recurrence, Local / prevention & control. Nurse's Role. Oncology Nursing. Photochemotherapy. Recombinant Proteins

MedlinePlus Health Information. consumer health - Skin Cancer.

Hazardous Substances Data Bank. Imiquimod .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19329898.001).

[ISSN] 0966-0461

[Journal-full-title] British journal of nursing (Mark Allen Publishing)

[ISO-abbreviation] Br J Nurs

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] England

[Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 76543-88-9 / interferon alfa-2a; 99011-02-6 / imiquimod

[Number-of-references] 26

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] The increase in tryptase- and chymase-positive mast cells is associated with partial inactivation of chymase and increase in protease inhibitors in basal cell carcinoma.

BACKGROUND: In basal cell carcinoma (BCC), mast cells accumulate in the peritumoral stroma.

The serine proteinases tryptase and chymase are the major mediators in mast cell granules and they may exert their enzymatic activity in the BCC lesion by inducing matrix remodeling and epithelial cell detachment.

OBJECTIVE: To analyse the numbers of mast cells showing tryptase enzyme activity, chymase enzyme activity and chymase immunoreactivity as well as the presence of chymase inhibitors alpha(1)-antichymotrypsin (alpha(1)-AC), alpha(1)-proteinase inhibitor (alpha(1)-PI) and squamous cell carcinoma antigen-2 (SCCA-2) in BCC.

METHODS: Eleven biopsies were taken from the lesion and healthy-looking skin of 10 patients with superficial spreading BCC.

RESULTS: In the BCC lesion, the number of mast cells with tryptase activity and chymase immunoreactivity was significantly increased by 2.2- to 2.3-fold.

However, the ratio of cells with chymase activity to those with chymase immunoreactivity was significantly decreased from 49 +/- 19% in the healthy skin to 33 +/- 19% in the BCC lesion.

Instead, the percentage of mast cells displaying alpha(1)-AC or alpha(1)-PI immunoreactivity was significantly increased by 1.7-fold in the BCC lesion.

SCCA-2 expression was strongly increased in the malignant BCC epithelium but mostly in the suprabasal layers.

CONCLUSIONS: Tryptase- and chymase-positive mast cells (MC(TC)) increased in the BCC lesion.

SCCA-2 increased in BCC, but was localized mostly to the suprabasal layers, and thus it seems not to be crucial in inhibiting chymase.

[MeSH-major] Carcinoma, Basal Cell / enzymology. Chymases / metabolism. Mast Cells / enzymology. Protease Inhibitors / metabolism. Skin Neoplasms / enzymology. Tryptases / metabolism

MedlinePlus Health Information. consumer health - Skin Cancer.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17658999.001).

[ISSN] 0926-9959

[Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV

[ISO-abbreviation] J Eur Acad Dermatol Venereol

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Netherlands

[Chemical-registry-number] 0 / Protease Inhibitors; EC 3.4.21.39 / Chymases; EC 3.4.21.59 / Tryptases

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Imiquimod 5% cream use for the treatment of basal cell carcinomas in elderly patients, in long-term care facilities, not amenable to surgical or radiation therapy.

[MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Basal Cell / drug therapy. Skin Neoplasms / drug therapy

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

MedlinePlus Health Information. consumer health - Skin Cancer.

Hazardous Substances Data Bank. Imiquimod .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17234120.001).

[ISSN] 1203-4754

[Journal-full-title] Journal of cutaneous medicine and surgery

[ISO-abbreviation] J Cutan Med Surg

[Language] eng

[Publication-type] Letter

[Publication-country] United States

[Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; P1QW714R7M / imiquimod

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Incidence of nonmelanoma skin cancer in a cohort of patients with vitiligo.

BACKGROUND: Nonmelanoma skin cancer (NMSC) incidence in patients with vitiligo has not been studied.

Age-adjusted incidence rates were: basal cell carcinoma, male 1382/100,000; basal cell carcinoma, female 0; squamous cell carcinoma, male 465/100,000; squamous cell carcinoma, female 156/100,000.

Except for basal cell carcinoma in females, all rates were higher than US rates but not statistically significant.

[MeSH-major] Skin Neoplasms / epidemiology. Vitiligo / complications

[MeSH-minor] Adolescent. Adult. Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Female. Humans. Male. Middle Aged. United States / epidemiology

Genetic Alliance. consumer health - Vitiligo.

MedlinePlus Health Information. consumer health - Skin Cancer.

MedlinePlus Health Information. consumer health - Vitiligo.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] J Am Acad Dermatol. 2009 Dec;61(6):1080-1 [19925933.001]

[Cites] Int J Cancer. 1991 Jan 2;47(1):12-9 [1985867.001]

[Cites] N Engl J Med. 1974 Dec 5;291(23):1207-11 [4422691.001]

[Cites] Clin Exp Dermatol. 1996 Jan;21(1):43-5 [8689768.001]

[Cites] J Eur Acad Dermatol Venereol. 2003 Sep;17(5):578-80 [12941100.001]

[Cites] J Am Acad Dermatol. 1998 May;38(5 Pt 1):647-66; quiz 667-8 [9591808.001]

[Cites] N Engl J Med. 1979 Apr 12;300(15):809-13 [423919.001]

[Cites] J Am Acad Dermatol. 2005 Aug;53(2):320-8 [16021129.001]

[Cites] Br J Dermatol. 2000 Apr;142(4):824-5 [10792246.001]

[Cites] Dermatol Surg. 2006 Dec;32(12):1473-9 [17199655.001]

[Cites] Clin Exp Dermatol. 1997 Jan;22(1):54 [9330057.001]

[Cites] Int J Cancer. 1999 May 17;81(4):555-9 [10225444.001]

[Cites] Arch Dermatol. 1995 Jun;131(6):734-5 [7778934.001]

[Cites] Int J Cancer. 1993 Apr 1;53(6):886-91 [8473047.001]

[Cites] Arch Dermatol. 1976 Nov;112(11):1531-4 [984858.001]

[Cites] J Am Acad Dermatol. 1998 Feb;38(2 Pt 1):268-70 [9486686.001]

[Cites] Acta Derm Venereol. 1996 Nov;76(6):429-32 [8982403.001]

[Cites] J Am Acad Dermatol. 1994 May;30(5 Pt 1):774-8 [8176018.001]

[Cites] Acta Derm Venereol. 1992 Aug;72(4):305-6 [1357897.001]

[Cites] J Am Acad Dermatol. 2006 Nov;55(5):741-60; quiz 761-4 [17052479.001]

[Cites] Cancer. 1995 Jan 15;75(2 Suppl):667-73 [7804993.001]

[Cites] J Am Acad Dermatol. 2001 Dec;45(6 Suppl):S227-9 [11712068.001]

[Cites] Br J Dermatol. 2000 Jul;143(1):219-21 [10886181.001]

[Cites] Photodermatol Photoimmunol Photomed. 2006 Aug;22(4):211-3 [16869872.001]

(PMID = 19375190.001).

[ISSN] 1097-6787

[Journal-full-title] Journal of the American Academy of Dermatology

[ISO-abbreviation] J. Am. Acad. Dermatol.

[Language] eng

[Grant] United States / NCI NIH HHS / CA / R01 CA140754

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The membrane underwent a bcc-fcc (body-centered cubic to face-centered cubic) phase transition between 723 and 873 K resulting in compositional segregation.

After reannealing at 723 K the alloy layer reverted to a bcc structure although a small fcc fraction remained behind.

The mixed-phase morphology was analyzed combining X-ray diffraction with scanning electron microscopy-energy-dispersive spectroscopic analysis (SEM-EDS) measurements, which revealed micrometer-scale Cu-enriched bcc and Cu-depleted fcc domains.

The prevalence of desorption as the permeation rate-limiting step below 454 K is attributed to the pairing of an extraordinarily high hydrogen diffusivity with a marginal hydrogen solubility in bcc PdCu alloys.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17715958.001).

[ISSN] 1520-6106

[Journal-full-title] The journal of physical chemistry. B

[ISO-abbreviation] J Phys Chem B

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Detection of basal cell carcinomas in Mohs excisions with fluorescence confocal mosaicing microscopy.

BACKGROUND: High-resolution real-time imaging of human skin is possible with a confocal microscope either in vivo or in freshly excised tissue ex vivo.

OBJECTIVES: To evaluate the sensitivity and specificity of ex vivo real-time imaging with fluorescence confocal mosaicing microscopy, using acridine orange, for the detection of residual basal cell carcinoma (BCC) in Mohs fresh tissue excisions.

METHODS: Forty-eight discarded skin excisions were collected following completion of Mohs surgery, consisting of excisions with and without residual BCC of all major subtypes.

Two Mohs surgeons, who were blinded to the cases, independently assessed confocal submosaics and recorded the presence or absence of BCC, location, and histological subtype(s).

RESULTS: The overall sensitivity and specificity of detecting residual BCC was 96.6% and 89.2%, respectively.

Very good correlation was observed between confocal mosaics and matched Mohs frozen sections for benign and malignant skin structures, overall tumour burden and location, and identification of all major histological subtypes of BCC.

CONCLUSIONS: Fluorescent confocal mosaicing microscopy using acridine orange enables detection of residual BCC of all subtypes in Mohs fresh tissue excisions with high accuracy.

This observation is an important step towards the long-term clinical goal of using a noninvasive imaging modality for potential real-time surgical pathology-at-the-bedside for skin and other tissues.

[MeSH-major] Carcinoma, Basal Cell / pathology. Mohs Surgery / methods. Skin Neoplasms / pathology

[MeSH-minor] Diagnosis, Differential. Humans. Microscopy, Confocal / methods. Microscopy, Fluorescence / methods. Sensitivity and Specificity

MedlinePlus Health Information. consumer health - Skin Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Surgery. 2000 Dec;128(6):1088-1100; discussion 1100-1 [11114647.001]

[Cites] J Microsc. 2009 Jan;233(1):149-59 [19196421.001]

[Cites] Arch Dermatol. 2004 Jun;140(6):736-42 [15210467.001]

[Cites] Arch Otolaryngol Head Neck Surg. 2004 Aug;130(8):923-8 [15313861.001]

[Cites] J Cell Biol. 1985 Apr;100(4):1309-23 [3920227.001]

[Cites] Dermatol Surg. 2004 Dec;30(12 Pt 1):1470-8 [15606734.001]

[Cites] J Biomed Opt. 2005 May-Jun;10(3):034009 [16229653.001]

[Cites] Br J Dermatol. 2006 Feb;154(2):305-9 [16433801.001]

[Cites] Opt Lett. 2006 Apr 1;31(7):942-4 [16599219.001]

[Cites] J Am Acad Dermatol. 2006 Sep;55(3):408-12 [16908344.001]

[Cites] Opt Lett. 2006 Sep 15;31(18):2756-8 [16936882.001]

[Cites] J Biomed Opt. 2007 Jan-Feb;12(1):014005 [17343480.001]

[Cites] Appl Opt. 2007 Apr 1;46(10):1843-51 [17356629.001]

[Cites] J Biomed Opt. 2007 May-Jun;12(3):034004 [17614712.001]

[Cites] J Biomed Opt. 2007 May-Jun;12(3):034027 [17614735.001]

[Cites] Lasers Surg Med. 2007 Oct;39(9):696-705 [17960751.001]

[Cites] J Biomed Opt. 2007 Sep-Oct;12(5):051901 [17994884.001]

[Cites] J Invest Dermatol. 2008 May;128(5):1248-55 [17989735.001]

[Cites] J Biomed Opt. 2008 Mar-Apr;13(2):024013 [18465976.001]

[Cites] Br J Dermatol. 2008 Jul;159(1):152-61 [18460029.001]

[Cites] J Biomed Opt. 2008 Jul-Aug;13(4):044016 [19021344.001]

[Cites] J Biomed Opt. 2008 Sep-Oct;13(5):054001 [19021381.001]

[Cites] J Invest Dermatol. 2001 Nov;117(5):1137-43 [11710924.001]

(PMID = 19416248.001).

[ISSN] 1365-2133

[Journal-full-title] The British journal of dermatology

[ISO-abbreviation] Br. J. Dermatol.

[Language] eng

[Grant] United States / NCI NIH HHS / CA / P30 CA008748; United States / NIBIB NIH HHS / EB / R01 EB002715; United States / NIBIB NIH HHS / EB / R01 EB002715-05; United States / NIBIB NIH HHS / EB / R01EB002715

[Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] England

[Other-IDs] NLM/ NIHMS95359; NLM/ PMC2693082

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Human herpesvirus type 6 and type 1 infection increases susceptibility to nonmelanoma skin tumors.

In order to investigate herpesvirus (HHV) role in the susceptibility to skin cancer, we compared HHV6 and HHV1 incidence in DNA samples extracted from 120 lesions and 41 normal skin tissues.

HHV6 (31.7%) and HHV1 (23.8%) were detected more frequently in skin cancer than in control individuals (14.6 and 5%, respectively) (P=0.0391 and P=0.00094, respectively).

The risk of presenting basal cell carcinomas (BCC) was more than 3 times higher for HHV-6 infected patients (OR=3.182; 95% CI: 1.125-8.997).

The risk for HHV-1 infected individuals of presenting BCC and squamous cell carcinomas was increased 8 and 6 times, respectively (OR=8.125; 95% CI: 1.735-38.043 and OR=6.290; 95% CI: 1.283-30.856, respectively).

[MeSH-major] Carcinoma, Basal Cell / etiology. Carcinoma, Basal Cell / virology. Carcinoma, Squamous Cell / etiology. Carcinoma, Squamous Cell / virology. Herpes Simplex / complications. Herpesvirus 1, Human / pathogenicity. Herpesvirus 6, Human / pathogenicity. Roseolovirus Infections / complications. Skin Neoplasms / etiology. Skin Neoplasms / virology

[MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy. Case-Control Studies. Child. DNA, Viral / analysis. Female. Humans. Incidence. Male. Middle Aged. Odds Ratio. Polymerase Chain Reaction. Risk Factors

MedlinePlus Health Information. consumer health - Herpes Simplex.

MedlinePlus Health Information. consumer health - Skin Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15914272.001).

[ISSN] 0304-3835

[Journal-full-title] Cancer letters

[ISO-abbreviation] Cancer Lett.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Ireland

[Chemical-registry-number] 0 / DNA, Viral

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Epigenetic silencing contributes to frequent loss of the fragile histidine triad tumour suppressor in basal cell carcinomas.

BACKGROUND: Extensive exposure to ultraviolet radiation is associated with genetic alterations in basal cell carcinomas (BCCs), which represent some 75% of skin cancers.

OBJECTIVES: As recent data suggested the fragile histidine triad (FHIT) gene product to participate in DNA damage responses we wished to address whether functional deletion of this tumour suppressor participates in the development of BCC.

METHODS: Paraffin-embedded specimens from 17 patients with BCC were available for methylation-specific polymerase chain reaction (MSP), combined bisulphite-dependent restriction analysis (COBRA) of the FHIT gene and immunohistochemistry of its product.

RESULTS: We report for the first time that 100% of BCCs are negative for FHIT by immunostaining.

Aberrant methylation of the FHIT promoter occurred in a significant portion of BCCs.

MSP detected hypermethylation of the FHIT/FRA3B locus in nine of nine (100%) periocular BCCs and in six of eight (75%) BCCs from other body regions.

COBRA yielded similar results, confirming that some 88% of the 17 BCCs analysed harbour epigenetic silencing of the FHIT gene.

CONCLUSIONS: We have identified epigenetic silencing of the FHIT tumour suppressor gene as a frequent inactivation mechanism which is likely to contribute to functional deficiencies in DNA damage response of BCCs.

[MeSH-major] Acid Anhydride Hydrolases / genetics. Carcinoma, Basal Cell / genetics. Gene Silencing. Genes, Tumor Suppressor. Neoplasm Proteins / genetics. Skin Neoplasms / genetics

MedlinePlus Health Information. consumer health - Skin Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17107382.001).

[ISSN] 0007-0963

[Journal-full-title] The British journal of dermatology

[ISO-abbreviation] Br. J. Dermatol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Neoplasm Proteins; 0 / fragile histidine triad protein; EC 3.6.- / Acid Anhydride Hydrolases

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Multiple basal cell carcinomas of the skin are another typical feature of Gorlin-Goltz syndrome.

Aberrant activation of sonic hedgehog signaling has been reported for sporadic and hereditary basal cell carcinoma caused by specific genetic mutations, but for keratocystic odontogenic tumors, the role of aberrant sonic hedgehog signaling has not yet been evaluated in detail.

This finding underlines the neoplastic character of this intraosseous lesion.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Cell. 1996 Jun 14;85(6):841-51 [8681379.001]

[Cites] J Pathol. 2001 Aug;194(4):473-7 [11523056.001]

[Cites] Cancer Res. 1997 Jun 15;57(12):2336-40 [9192803.001]

[Cites] Br J Oral Maxillofac Surg. 1997 Feb;35(1):46-8 [9043004.001]

[Cites] J Can Dent Assoc. 2008 Mar;74(2):165-165h [18353202.001]

[Cites] J Mol Med (Berl). 1999 Jun;77(6):459-68 [10475061.001]

[Cites] Cancer. 1992 Dec 15;70(12):2988-94 [1451083.001]

[Cites] Anticancer Res. 2003 Sep-Oct;23(5A):3971-7 [14666705.001]

[Cites] J Oral Maxillofac Surg. 2006 Mar;64(3):379-83 [16487797.001]

[Cites] Am J Pathol. 2006 Sep;169(3):806-14 [16936257.001]

[Cites] J Clin Pathol. 2001 Dec;54(12):897-910 [11729208.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Jun 10;100(12 ):7331-6 [12777630.001]

[Cites] Int J Oral Maxillofac Surg. 2004 Sep;33(6):584-92 [15308259.001]

[Cites] Development. 1998 Aug;125(15):2803-11 [9655803.001]

[Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]

[Cites] Mund Kiefer Gesichtschir. 2006 Jan;10(1):1-2 [16328532.001]

[Cites] J Oral Pathol. 1988 Jan;17(1):39-42 [3131508.001]

[Cites] Pathol Int. 1999 Aug;49(8):687-94 [10504535.001]

[Cites] Am J Med Genet. 1997 Mar 31;69(3):299-308 [9096761.001]

[Cites] Hum Mol Genet. 2001 Apr;10 (7):757-62 [11257109.001]

[Cites] Oncol Rep. 2006 May;15(5):1141-5 [16596176.001]

[Cites] Mund Kiefer Gesichtschir. 2002 Nov;6(6):394-401 [12447651.001]

[Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998 Jul;86(1):42-7 [9690244.001]

(PMID = 19082818.001).

[ISSN] 1433-0458

[Journal-full-title] HNO

[ISO-abbreviation] HNO

[Language] ger

[Publication-type] English Abstract; Journal Article

[Publication-country] Germany

[Chemical-registry-number] 0 / Hedgehog Proteins

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Aggressive basal cell carcinoma with invasion of the parotid gland, facial nerve, and temporal bone.

Aggressive variants of basal cell carcinoma (BCC), such as infiltrating, morpheaform, and basosquamous types, are associated with invasion of underlying tissues and are often difficult to treat.1 BCCs located in embryonic fusion planes, such as the periauricular region, are thought to exhibit deep extension and, subsequently, high recurrence rates, although this theory has been challenged and remains controversial.2-4 Despite the known features of aggressive BCC, parotid gland invasion and temporal bone and facial nerve involvement are rarely reported occurrences.

We describe two patients with morpheaform BCC in the periauricular region demonstrating direct invasion of the parotid gland and concomitant facial nerve involvement.

These patients require complex surgical management, as highlighted in this report.

[MeSH-major] Bone Neoplasms / pathology. Carcinoma, Basal Cell / pathology. Head and Neck Neoplasms / pathology. Nervous System Neoplasms / pathology. Parotid Neoplasms / pathology

[MeSH-minor] Aged. Facial Nerve / pathology. Humans. Male. Neoplasm Invasiveness. Otorhinolaryngologic Surgical Procedures. Skin Neoplasms / pathology. Skin Neoplasms / surgery. Temporal Bone / pathology

MedlinePlus Health Information. consumer health - Bone Cancer.

MedlinePlus Health Information. consumer health - Head and Neck Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16442061.001).

[ISSN] 1076-0512

[Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]

[ISO-abbreviation] Dermatol Surg

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States